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General introduction
Cancer-related pain
Pain is an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage, according to the widely used 
definition from the International Association for the Study of Pain (1). The prevalence of 
pain is high in patients with cancer. In a meta-analysis of 52 studies, a pooled prevalence 
rate of 53% was found; ranging from 33% of patients after curative treatment, to 64% 
of patients with advanced stages of disease. More than one-third graded their pain as 
moderate or severe (2). In a later published pan-European survey study, 72% of 4947 cancer 
patients approached, reported moderate to severe pain at least monthly (3).
Although the prevalence differs among cancer types, pain can occur in all types of cancer. 
In up to 90% the pain is caused by the cancer itself, while in about 20% the treatment of 
cancer (surgery, radio-or chemotherapy) is the cause of pain (4). Pain can also be associated 
with general debility or with concurrent conditions unrelated to the cancer. The majority of 
patients suffer from more than one pain, and a median of 3 different pain sites has been 
reported (5-7). 
Pain can have a large impact on daily life and leads to distress in about two thirds of patients. 
In the European survey study, 51% reported difficulties in concentrating or thinking, 69% in 
performing normal activities in daily life, 52% in work performance and 30% in caring for self 
or others. In addition, 43% felt that their pain made them an increased burden to others (3). 
Several factors influence the subjective experience of pain. These factors can be broadly 
divided into three domains: physical processes, thoughts and feelings and behaviour 
(8). Within the physical domain, peripheral (pain receptors, sensory nerves) and central 
mechanisms as well as modulating systems (e.g. gate control theory, sensitisation, 
neurotransmitters) can influence the pain sensation (8). 
Opioids 
An opioid is any agent that binds to opioid receptors. The original opiates, morphine and 
codeine, were derived from opium. In search of a better balance between analgesia and 
side-effects, numerous (semi-) synthetic opioids have been developed. In the Netherlands, 
commonly prescribed opioids are morphine, oxycodone, fentanyl, methadone and 
hydromorphone. Opioids act by binding to opioid receptors that can be found throughout 
the nervous system, but also in sites unrelated to pain modulation such as the intestinal 
tract. There are three principal classes of receptors, named mu (µ), delta (δ) and kappa 
(κ) receptors, all G-coupled protein receptors. The effects of an opioid depend upon the 
receptor to which it binds, its affinity for that receptor, and whether the opioid is an agonist 
or an antagonist. 
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1The available opioids each have their own pharmacological characteristics, are available 
for different routes of administration and are metabolized through different pathways 
(Table 1). Differences in bioavailability, production of active metabolites and elimination 
are likely to influence outcomes of treatment.
Treatment of cancer-related pain
The World Health Organisation three-step analgesic ladder (9) (Figure 1) forms the basis 
for the treatment of cancer-related pain. By using this stepped approach, satisfactory pain 
relief can be reached in 80-90% of patients (10-12).
According to the WHO Pain ladder, strong-acting opioids are the treatment of choice 
for moderate to severe cancer-related pain after failure of treatment with a weak-acting 
opioid. In daily practice, step II opioids are often omitted and low doses of morphine or 
oxycodone are introduced after step I. This two-step strategy is supported by a recently 
published randomized trial showing that low doses of morphine reduced pain intensity 
significantly as compared to weak (step II) opioids with similar tolerability (13). 
Based on currently available evidence, it is unknown which type of opioid is best to start 
treatment with. The evidence based guidelines from the European Association for Palliative 
Care (EAPC) state that ‘data show no important differences between morphine, oxycodone, 
and hydromorphone given by the oral route) and permit a weak recommendation that any 
one of these three drugs can be used as the first choice step III opioid for moderate to 
severe cancer pain (14). 
Unfortunately, in 25-40% of patients, first line treatment is unsuccessful due to insufficient 
pain control and/or the occurrence of severe side effects limiting (further) dose escalations 
(15, 16). Common opioid induced side effects are gastro-intestinal (e.g. nausea, vomiting, 
constipation), central (e.g. drowsiness, hallucinations, delirium, myoclonus, respiratory 
depression), autonomic (e.g. dry mouth) and cutaneous (e.g. sweating, itch) effects (15). 
Central side effects, such as drowsiness and confusion and gastro-intestinal side effects 
are most frequently reported as dose limiting adverse effects (16, 17). In these cases opioid 
rotation is reported to be successful in about two-thirds of patients (18, 19). In clinical 
practice, several drugs may need to be tried in order to find the one with the best balance 
between analgesic and adverse effects. In addition, doses need to be carefully titrated to 
avoid overdosing and toxicity. As there is no standard or maximal dose, in each patient, the 
dose must be titrated based on clinical effects. Thus, due to the wide variability in treatment 
effects and doses, treatment with opioids for managing cancer-related pain needs to 
be individualized. As it is unknown which factors can guide treatment, a trial- and-error 
approach is used in clinical practice. This takes time, which is unwanted in a population 
with often limited life-expectancy. There is therefore an urgent need of expanding our 
knowledge and finding predictive factors that can help in guiding treatment.
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This thesis describes research that was performed in order to expand our knowledge of the 
effects of treatment with individual opioids and to better understand causes of variations 
in treatment outcomes. 
Opioid for moderate to severe pain
± Non-opioid
± Adjuvant 3
2
1
Opioid for mild to moderate pain
± Non-opioid
± Adjuvant
Freedom from cancer pain
Pain persisting or increasing
Non-opioid
± Adjuvant
Pain persisting or increasing
Pain
Figure 1. World Health Organisation Pain ladder
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Type of opioid Route of 
administration
Equi-analgesic
dose
Summary of metabolism Notes
Pure µ agonists
Morphine IM/IV/SC 
Oral (SR, IR) 
(spinal, rectal)
20 mg
60 mg
Phase 2; Glucuronidation by UGT2B7 
Main Metabolites: morphine-6-
glucuronide (M6G; 10-15%, active) and 
morphine-3-glucuronide (M3G; 45-55%, 
active?)
Elimination: urinary; 75% M3G, 10% 
morphine
T ½: 1.5-3 h, increased in renal failure
Extensive first-pass 
metabolism
Minor metabolism to 
hydromorphone
No potential drug-drug 
interactions identified
Oxycodone IM/IV/SC 
Oral (SR, IR) 
20 mg 
40 mg 
Phase 1; CYP3A4 and to a lesser extent 
CYP2D6
Main metabolites: Noroxycodone (80% 
-active), oxymorphone (10% - active)
Elimination: 72% urinary (metabolites)
T ½ : 2-3 h
Conflicting evidence on 
effects of CYP3A4 and CYP2D6 
genotypes
Probably also an agonist for 
the Kappa2b opioid receptor 
(24) 
Fentanyl IV/SC 
Transdermal 
Nasal/buccal/
sublingual 
25 mcg/h
25 mcg/h
–
Phase 1, CYP3A4
Main metabolite: Norfentanyl (inactive)
Elimination: 75% urinary (metabolites)
T ½ : 7-12 h (parenteral)
High lipid solubility 
Only 0.4-6% excreted 
unchanged
T ½ up to 22 h after repeated 
patches (25)
Hydromorphone IM/IV/SC
Oral (SR, IR) 
3-4 mg
15 mg
Phase 2, glucuronidation by UGT2B7 and 
to a lesser extent UGT1A2
Main metabolite: hydromorphone-3 
glucuronide (active)
Elimination: urinary excretion
T ½ : 2-3 h
Extensive first pass 
metabolism
In our hospital used mainly 
for continuous parenteral 
administration in patients 
failing treatment with high 
doses of other opioids 
Methadone IM/IV/SC
Oral 
20 mg 
40 mg
Controversial, Phase 1, CYP3A4, CYPD2B6
Main metabolite: EDDP (inactive) 
Elimination: variable; 50-75% urinary 
(methadone, EDDP), faecal elimination
T ½ : 12-150 h (longer after prolonged 
administration)
Also antagonizes the NMDA- 
receptor and functions as 
serotonin and norepinephrine 
reuptake inhibitor
Elimination half-live and 
potency highly variable 
Partial µ agonist
Buprenorphine IM/IV/SC
Transdermal 
Sublingual
0.6 mg
+- 35 mcg/hr
Phase 1 CYP3A4 (30%) CYP2C8 &Phase 2 
glucuronidation UGT2B7, UGT1A1
Main metabolite: norbuprenorphine 
(active)
T ½ : 1-7 h
Elimination: 70% faecal as conjugated 
metabolites, 14-30% urinary 
Antagonist kappa and delta 
receptors
May precipitate opioid 
withdrawal effects when 
administered after recent use 
of opioid agonists.
Possible ceiling effect
IM = intramuscular; IV = intravenous; SC = subcutaneous; SR= slow-release; IR= immedi-
ate-release; UGT = Uridine 5’-diphospho-glucuronosyltransferase; CYP= Cytochromes P450; 
EDDP = 2-ethylidine-1,5-dimethyl-3,3-diphenylpyrrolidine; NMDA = N-methyl-D-Aspartate
Table 1. Overview of characteristics of commonly used opioids (20-23)
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The aims of this thesis are:
1.  To study the role of treatment with opioids and 
other medication in patients with an indication 
for palliative sedation due to severe, refractory 
symptoms. 
2.  To report the incidence of side effects of 
opioids in patients naive to strong acting 
opioids and to study possible differences in the 
incidence of side effects between the opioids. 
3.  To gain more insight in the pharmacokinetics 
of morphine and fentanyl administered by 
different routes. 
4.  To explore whether variability in 
pharmacokinetics of morphine and fentanyl 
is associated with treatment outcomes and to 
translate pharmacokinetic findings to clinical 
practice.
5.  To study the effects of clinical and demographic 
factors and genetic variations on outcomes of 
treatment with opioids.
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1Outline of this thesis
In chapter 2, we studied a population of patients with a particularly bad outcome, namely 
patients who died on our specialized unit for palliative care after continuous palliative 
sedation because of severe, refractory symptoms. To explore the possible role of opioids 
and other medication in this setting, we studied differences in medication use between 
these patients and patients who died without an indication for palliative sedation. 
In chapter 3, a systematic review of studies reporting adverse events of morphine, 
fentanyl, oxycodone and methadone in patients with cancer-related pain not treated 
with any of these opioids before is reported. The aim of this review was to describe the 
incidence of adverse events per type of opioid and to compare these rates in order to find 
possible differences that can help to guide treatment. 
In chapter 4, we present results from a population pharmacokinetic study on fentanyl 
administered by the subcutaneous and transdermal routes. Although titration with 
subcutaneous fentanyl is safe and effective, pharmacokinetic data are lacking. We 
therefore aimed to describe the pharmacokinetics of subcutaneous and transdermal 
fentanyl in one cohort of patients. Secondly, we aimed to evaluate rotations from 
subcutaneous to transdermal fentanyl.
In chapter 5, we describe results from a population pharmacokinetic study on morphine 
administered subcutaneously and orally. Secondly, we studied the effects of several 
clinical and genetic factors on the clearance of morphine and metabolites and explored 
whether variability in clearance of morphine and metabolites was related to treatment 
outcome. 
In chapter 6, results from an explorative analysis are presented, in which we compared 
patients in whom treatment with opioids and/or specific opioids failed with patients in 
whom these treatments did not fail  and explored a range of clinical and genetic factors 
for associations with treatment failure. 
Chapter 7 summarises the studies described in this thesis and addresses possibilities for 
future studies.
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Chapter 2
    Higher doses of opioids 
in	patients	who	need	
palliative	sedation	 
prior to death: 
cause or consequence? 
    A.W.Oosten, W.H. Oldenmenger, C. van Zuylen, P.I.M. Schmitz,  
M. Bannink, P.J. Lieverse, J.E.C. Bromberg, C.C.D.van der Rijt
   Eur J Cancer. 2011 Oct;47(15):2341-6 
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Abstract
Background: 
Palliative sedation (PS) is necessary in a significant percentage of patients dying on an 
acute palliative care unit (PCU). Common indications are terminal restlessness, pain and 
dyspnoea. On our PCU, terminal restlessness was the main indication for PS but pain was 
the most prevalent symptom during admission. Because delirium is often drug induced in 
terminal cancer patients and opioids are amongst the most frequently implicated drugs, 
we hypothesised that the underlying pain problem and its treatment might have been 
related to the need for sedation. 
Patients and methods: 
To test this hypothesis, we did a retrospective analysis on the use of medication with 
potential cognitive side effects, focusing on analgesics, in 68 patients who died on the 
PCU after PS and 89 patients who died without PS. 
Results: 
Ultimately sedated patients used opioids in significantly higher doses; they were more 
often treated with a rotation to another opioid and with amitriptyline. The dose of opioids 
used at various time points between admission and death was strongly related to the 
probability of PS.
Conclusions: 
Our findings support the hypothesis that, although pain was not the main indication for 
PS, pain and its treatment might have been primarily related to the need for palliative 
sedation in this patient cohort.
21
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Introduction
Palliative sedation (PS) is the monitored use of medication intended to induce varying 
states of unconsciousness, but not death, in order to relieve refractory and unendurable 
symptoms in patients in whom death is imminent (1). This implies that PS is only justified 
when unendurable symptoms are present that cannot be controlled with appropriate 
measures.
Common indications for PS are pain, terminal restlessness/delirium/confusion and 
dyspnoea. In some reported series delirium or confusion/restlessness was the most 
frequent indication for PS (2-4) while in other series dyspnoea (5, 6) or pain (7-9) were 
found to be the most frequent indications.
The practice of palliative sedation in our specialised unit for acute palliative care in a 
university cancer hospital in the Netherlands has been reported by Rietjens et al (10). They 
described 157 patients who died at this unit, and studied differences between 68 sedated 
and 89 non-sedated patients. They found that terminal restlessness was the most common 
indication for PS (60%), followed by dyspnoea (46%) and pain (26%). Pain, however, was 
the most prevalent symptom on admission (up to 87%), and its prevalence remained 
high during admission – both for patients who died after PS as for patients who were not 
sedated before death. Prior to the onset of sedation, sedated patients more often suffered 
from delirium as compared to non-sedated patients at similar periods before death. 
As it is known that delirium is often drug induced in advanced cancer patients and, more 
specifically, that opioids are amongst the most frequently implicated drugs (11-14), it is 
possible that the underlying pain problem and its treatment were primarily related to the 
need for sedation. In this new retrospective analysis, we therefore studied differences 
in the use of medication with potential cognitive side-effects, with special attention 
for opioids and other, adjuvant, drugs used in the treatment of complex pain, between 
patients who were ultimately sedated prior to death and patients dying without sedation.
Patients and methods
We conducted a new retrospective analysis of data from the same cohort of patients that 
was studied by Rietjens et al (10). The cohort consisted of all patients who died on our 
specialised acute palliative care unit (PCU) in a tertiary cancer hospital in Rotterdam, 
The Netherlands between October 2001 and October 2005. 
The main goal during admission to the PCU is to provide symptom control for cancer 
patients with advanced disease. Daily multidisciplinary meetings are held with medical 
oncologists, nurses, an anesthesiologist, a neurologist and a psychiatrist present; other 
specialists are consulted when needed. 
22
Pain is treated stepwise following the WHO pain medication ladder (15). Of note, because 
many patients on the PCU are admitted with complex pain problems, high doses of opioids, 
opioid rotation, parenteral administration of opioids and/or adjuvant analgesics are often 
needed. In patients with severe pain, we generally use parenteral morphine or fentanyl 
for titration, if possible subcutaneously. Doses are titrated whilst closely monitoring the 
effect on pain and side-effects. Patients are monitored for the development of delirium 
using the Delirium Observation Screening (DOS) scale, a Dutch-developed 13 point nurse 
observation scale filled out three times daily (16). For all patients who score ≥ 3 points 
or when delirium is suspected on clinical grounds, the psychiatrist is consulted. In case 
of dose-limiting side-effects that cannot be controlled with symptomatic therapy and/or 
inadequate effect on pain, opioid rotation to another type of opioid is used. We reserve 
the use of parenteral hydromorphone for patients whose pain cannot be controlled with 
high doses of other opioids, when dose-limiting side-effects occur related to other opioids 
or when problems related to the administration of large volumes subcutaneously arise. In 
these circumstances, ketamine may also be used as an adjuvant drug.
A decision to use palliative sedation in a dying patient is discussed in a multidisciplinary 
meeting. In case of sedation, opioids are continued at the dose level used at the start of 
the sedation, according to (inter)national guidelines. 
A detailed description of the data collection and analysis is given in the original article (10). 
In summary, the database was built in four time frames: admission (T0), 72-49 h before 
death (T1), 48-25 h before death (T2) and 24-0 h before death (T3). Baseline variables were 
scored on admission, other variables in the three time frames prior to death. The start of 
palliative sedation was not per se related to the time frames but could take place between 
admission and time of death. 
Regarding medication, we studied the use of: acetaminophen/NSAIDs, opioids, ketamine, 
amitriptyline, anti-convulsants, corticosteroids, benzodiazepines, anti-hypertensive 
drugs, diuretics, anti-emetics and acid reflux/stomach medication. In the category of 
opioids we differentiated various types of opioids in the time frames prior to death and 
registered rotations to another type of opioid . 
Per time frame, doses of all opioids administered (continuous, slow release and 
immediate release products) were recalculated to the morphine equivalent daily dose 
(MED) per 24 h. This was done according to published equianalgesic dose tables: oral 
morphine 60 mg/d = parenteral morphine 20 mg/d = transdermal fentanyl 25 mcg/h = 
parenteral fentanyl 25 mcg/h = oral oxycodone 30 mg/d = oral hydromorphone 8 mg/d 
= parenteral hydromorphone 4 mg/d (17-19). Conversion rates for tramadol, methadone 
and epidurally or intrathecally administered opioids are not included in these tables. For 
tramadol we used a conversion rate of 4:1 (tramadol:morphine), according to results of 
a study by Wilder-Smith in 1994 (20). For oral methadone we used a conversion factor 
23
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of 1: 4.7 (methadone:morphine), according to data from a study by Walker et al (21). For 
epidurally or intrathecally administered opioids no relevant studies could be found. We 
therefore decided to use conversion factors of 1:30 (epidural:oral morphine) and 1:300 
(intrathecal:oral morphine), respectively, factors based on theory and clinical experience 
of pain specialists from the department of anaesthesiology in our hospital.
Statistical analyses
Data were analysed using STATA version 10. Descriptive statistics were used to describe 
patients’ characteristics. Reported p-values are two-tailed and p < 0.05 was considered to 
be statistically significant. To assess the association between the MED and the probability 
of PS logistical regression analysis was used. For each interval we calculated logistic 
regression of sedation (yes or no) versus log (MED). So, we obtained the probability of 
sedation for each MED-value and for all time periods.
Results
Patient characteristics of 68 sedated and 89 non-sedated patients are given in Table 1. 
In case of sedation, it was started in the last 24 hrs before death in a majority of patients 
(68%). 
Symptom prevalence on admission and the indications for palliative sedation are shown in 
Table 2. There was a high prevalence of pain in both groups.
One patient in the sedated group was excluded from further analyses, because no 
information on used medication could be found. 
No statistically significant differences were found in the percentage of patients using anti-
convulsants, corticosteroids, anti-hypertensive drugs, diuretics, anti-emetics and acid 
reflux/stomach medication in T0-T3. Significantly more patients in the ultimately sedated 
group used benzodiazepines at T0, 10/68 (22%) sedated versus 2/89 (3%) non-sedated 
patients (p = 0.002). For T1-3 data could not be used as the indication for benzodiazepines 
was not registered, so they could then also be used for the purpose of PS.
The use of pain medication is shown in Figure 1. No significant differences were found in 
the percentage of patients using WHO step 1 pain medication and opioids (Figure 1a). The 
figure shows that the percentage of patients using WHO step 1 medication decreased with 
time, whilst the percentage of patients using opioids increased in both groups. 
Figure 1b shows that sedated patients more frequently used amitriptyline in T0-2. 
(p = 0.02, p = 0.002, p = 0.004, respectively). Between T0 and T1 the percentage of patients 
using ketamine in the ultimately sedated group increased from 4.5% to 13.4%, whereas it 
remained stable in the non-sedated group (differences NS).
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Figure 1. Differences in the use 
of pain medication and halo-
peridol between sedated and 
non-sedated patients.
Figure 1A: WHO step 1& 3 pain medication
Figure 1B: adjuvant analgesics
Figure 1C: haloperidol 
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Sedated patients
N = 68
Non sedated patients
N = 89
p-value
N % N %
Male 31 46 40 45 0.87
Age median (range) 57 (27-89) 61 (25-80) 0.03
Primary tumor
Lung 15 22 12 13 0.19
Gastro-intestinal 14 21 5 6 < 0.01
Breast 11 16 22 25 0.16
Genito-urinary tract 7 10 17 19 0.13
Head and neck 5 7 5 6 0.66
Melanoma 8 12 6 7 0.27
Sarcoma 5 7 7 8 0.91
Other/(A)CUP 3 4 15 17 0.02
Table 1. Patient characteristics
 Sedated patients
N = 68 
Non sedated patients
N = 89
p- value
Symptom prevalence on admission N % N %
Pain 59 87 69 78 0.2
Dyspnea 20 29 28 31 0.7
Delirium 8 12 9 10 0.8
Anxiety 6 9 6 7 0.7
Indication for palliative sedation
Pain 18 26 - -
Pain as the only indication for PS 7 10 - -
Terminal restlessness 41 60 - -
Dyspnea 31 46 - -
Other 10 15 - -
Table 2. Symptom prevalence on admission and indications for palliative sedation
(Main results of previous analyses)
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Figure 1c shows that about 40% of the ultimately sedated patients used haloperidol in T1 
and T2, whereas this percentage was about 20% for the non-sedated group (p = 0.02 and 
p = 0.034 respectively). 
Variations regarding the use of specific types of opioids and the various routes of 
administration were studied per time frame. At T0, patients from the ultimately sedated 
group and the non-sedated group used similar types of opioids. Many patients were 
rotated from oral to parenteral opioids during admission, but especially between T0 and 
T1, without differences between the groups. Between T0 and T1, rotation to another type 
of opioid was more often used in the group of patients who were ultimately sedated than 
in the non-sedated group: in 30/68 pts (44%) and 19/89 pts (22%), respectively (p < 0.005). 
In particular, more patients were set on hydromorphone (9.3 versus 1.2%, p = 0.017) or 
spinal pain medication (4.5 versus 1.2%, NS) during this period. There were no significant 
differences in the use of opioid rotations between sedated and non-sedated patients 
during the last 72 h of life.
The median morphine equivalent daily dose (MED) of opioids in T0-3 for sedated and non-
sedated patients is shown in Figure 2. Sedated patients used significantly higher doses of 
opioids in all time frames (p = 0.025, p = 0.001, p < 0.001, p < 0.001, respectively). 
One patient was found to use extremely high doses of opioids. Because the possibility 
of an error in noting the dose could not be excluded, this patient was excluded for the 
analyses on equianalgesic doses of opioids. 
Figure 3 shows the probability of dying with PS in relation to the logarithm of the MED 
of opioids at T0 using logistic regression analysis. The figure shows that there was a 
strong relationship between the dose of opioids at T0 and the probability of becoming 
Figure 2. Median equianalgesic dose of opioids per time frame.
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sedated before death (p = 0.017). Similar results were obtained for time frames T1 and T2 
(p = 0.004) and p < 0.001). 
Discussion
PS is necessary in a significant percentage of patients dying on an acute PCU (3, 5). These 
patients suffer from treatment refractory symptoms distressing them as well as their 
family members and care givers. The setting in which PS is performed, is therefore always 
difficult and stressful, making it all the more important to better understand the trajectory 
leading to PS and the factors that may influence it.
As mentioned in the introduction of this article, in some settings delirium or terminal 
restlessness/confusion is the main indication for PS whilst in others dyspnoea or pain is the 
main indication. To our knowledge, studies on predictors for the occurrence of refractory 
symptoms in the dying phase have not been performed. 
In our cohort of patients pain was one of the main indications for PS in 26% of patients, 
and the only indication in 10% of patients - although pain was very prominent. This reflects 
the fact that we have the facilities and the experience to treat patients with severe and 
difficult pain problems. However, pain and its treatment might very well be indirectly 
related to the need for PS as it is known that delirium is often drug induced. Because in 
our cohort of patients, delirium/terminal restlessness was the main indication for PS, we 
studied differences in medication with potential cognitive side-effects between ultimately 
sedated patients and non-sedated patients. We found some striking differences in the 
Figure 3. Probability of PS in relation to the MED of opioids on T0, logistic regression analysis.
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use of pain medication. The ultimately sedated patients used opioids in significantly 
higher doses; they were more often treated with a rotation to another type of opioid - in 
some to hydromorphone - and with adjuvant amitriptyline. Furthermore, ketamine and 
spinal medication were used more frequently, although differences were not statistically 
significant. These results support our hypothesis of more difficult pain problems in the 
ultimately sedated group compared to the non-sedated patients. Although it is likely that 
sedated patients had more severe pain, we unfortunately have no data to substantiate this 
as the severity of pain was not registered in the database in this study period. However, 
in our previous analyses in this same group of patients we already found indications to 
suggest a more aggressive course of the underlying cancer in the sedated patients, which 
is also compatible with the assumption of more difficult pain problems in this group of 
patients (10). Thus, ultimately sedated patients are likely to have had more difficult pain 
problems, leading to more intense treatment with a higher risk of terminal restlessness/
delirium. 
Differences in pharmacokinetics and pharmacodynamics of pain medication between 
the groups may also be important. It is possible that ultimately sedated patients had less 
analgesic effects and/or more side-effects from the used medication. Large inter-individual 
differences in the metabolism of morphine have indeed been described (22, 23) and 
genetic variability is assumed (24). Results of studies on the relation between morphine 
metabolites and delirium in cancer patients are conflicting, however (25-28). Furthermore, 
a recently published large European study could not find an association between genetic 
variability and opioid dose (29). More research on the effects of pharmacokinetic and 
pharmacogenetic variability on analgesic and side-effects of opioids is needed. 
To our knowledge, this is the first study addressing the possible role of pharmacological 
interventions for the treatment of complex pain in the need for PS in a group of terminally 
ill cancer patients. Although the retrospective design of our study is an important 
limitation, our findings indicate that more insight in the pathophysiologic mechanisms of 
refractory symptoms in the dying phase is needed.
In conclusion, our findings suggest that ultimately sedated patients had more difficult pain 
problems and/or had a disturbed dose-effect relationship for opioids. The more intensive 
treatment of these patients could have led to a higher rate of treatment refractory 
delirium/terminal restlessness, sometimes necessitating PS. Although pain was not the 
main indication for PS in our cohort of patients, its treatment might very well have been 
related to the need for PS. This emphasizes the need for more individualised treatment 
schemes, to minimise the risk of adverse events. 
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Abstract 
Data on the tolerability of opioids in patients with cancer-related pain are limited. Here, 
we report a systematic review that includes all published prospective studies reporting 
adverse events (AEs) of morphine, oxycodone, fentanyl, methadone, or hydromorphone 
for cancer-related pain in patients naive for these opioids. We included 25 studies 
describing 31 treatment cohorts, made an overview of study characteristics, and reported 
rates of AEs per type of opioid. The frequency of the most commonly reported AEs varied 
widely: nausea from 3 to 85%, vomiting from 4 to 50%, constipation from 5 to 97%, 
drowsiness from 3 to 88%, and dry mouth from 1 to 94%. There was a large heterogeneity 
among included studies, especially regarding the assessment and reporting of AEs. We 
describe how differences in assessment and reporting influence outcome rates. Although 
AEs are an important issue in daily clinical practice, realistic incidence rates of AEs per 
type of opioid are unknown because of the immense heterogeneity among studies.
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Introduction
Pain is prevalent in patients with cancer in all stages of the disease, with the highest 
prevalence seen in patients with advanced or metastatic disease: 2 of 3 patients experience 
pain, with more than one-third of these patients grading their pain as moderate or severe 
(1). The analgesic ladder as published by the World Health Organization (WHO) is the 
foundation for the treatment of cancer-related pain. WHO follows a stepwise approach, 
with weak-acting or step 2 opioids as second-line choice for moderate pain and strong-
acting step 3 opioids as third-line choice for moderate to severe pain (2). This review 
focuses on the strong-acting opioids (referred to as opioids in this article), which are also 
used as a first-line opioid in low doses.
Commonly prescribed opioids in the Western world are morphine, oxycodone, fentanyl, 
and, to a lesser extent, hydromorphone and methadone. Choosing among these opioids 
is not easy. Only a few randomized controlled trials (RCTs) directly comparing different 
opioids have been published, and no significant differences in efficacy and tolerability 
profiles have been shown, with the exception of the finding of less constipation with 
fentanyl compared with morphine (3-5). The European Association for Palliative Care 
guidelines state that morphine, oxycodone, or hydromorphone can be used as the first-
choice opioid and that fentanyl may be an alternative in some patients, for example in 
cases of problematic oral intake, renal insufficiency, or severe constipation. Methadone 
should be used only by experienced professionals (6).
The effect on pain and the occurrence of side effects in an individual patient are assumed to 
be the result of a complex interplay between pharmacokinetics and pharmacodynamics. 
Pharmacogenetics may further complicate existing pharmacokinetic-pharmacodynamic 
relationships Therefore, much research is conducted with the aim of finding clinical, 
pharmacokinetic, or genetic determinants that will enable true personalized treatment. 
However, results of such studies have not yielded specific markers or profiles that can 
guide treatment decisions for individual patients (7-9).
As a result, finding the right opioid in the right dose at the right moment is a matter of 
trial and error in daily clinical practice. The choice for the opioid to start with in an opioid-
naive patient is mainly based on expert opinions, clinical experience, personal preference, 
and sometimes clinical factors (ie, accessible routes of administration, renal failure). All 
opioids have shown equal rates of pain control (6, 10) but data about side effects are 
scarce. Obviously, if one of the opioids had a better side effect profile, this opioid would 
be preferred. Also, differences in the incidence of specific side effects can be relevant in 
patients who already present with or are at risk for various symptoms. The prevalence 
and severity of symptoms are high in patients with cancer-related pain and increase with 
each step up the WHO treatment ladder (11). In one study, patients not using any opioids 
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experienced a mean of 2.9 (standard deviation [SD] 1.9) symptoms. Among the most 
prevalent symptoms were insomnia (58%), anorexia (40%), constipation (25%), and nausea 
(21%) (12). We conducted a systematic review including prospective studies in patients 
with cancer naive for morphine, oxycodone, fentanyl, methadone, and hydromorphone 
in which side effects of these commonly used opioids were reported. The objective of this 
review was to create an overview of the incidence of side effects after starting treatment 
with opioids for cancer-related pain and to study whether the incidence of (specific) side 
effects differs among different types of opioids.
Methods
We performed a systematic review in which we included prospective studies reporting on 
the occurrence of side effects after the start of morphine, oxycodone, fentanyl, methadone, 
or hydromorphone for cancer-related pain in patients who were naive for these opioids. 
Pretreatment with codeine phosphate, dihydrocodeine, dextropropoxyphene, or tramadol 
was allowed.
The following databases were searched up until March, 2015: MEDLINE (PubMed), Embase, 
Web of Science, and the Cochrane Database of Systematic Reviews. No year limits were 
applied to the searches and therefore they extend as far back as the year range of each 
database. Retrievals in Ovid MEDLINE go back to 1976, EMBASE to 1985, Web of Science 
to 1950, and the Cochrane Library to 1966.
The search terminology included different terms and medical subject headings for 
cancer, side effects and specific side effects (constipation, nausea, vomiting, delirium, 
hallucinations, myoclonus, sweating, drowsiness, and dry mouth), all types of trials, and 
morphine, fentanyl, oxycodone, methadone, and hydromorphone. The search strategies 
were developed specifically for each database. The search was performed by a staff 
member of the Medical Library and one of the authors (A.W.O.). In addition, reference lists 
of relevant studies and reviews found were checked.
Two reviewers (A.W.O., W.H.O.) independently assessed all titles with or without abstracts 
identified by the search. In case of potentially relevant articles, the full text was obtained 
to judge if they fulfilled the criteria: 1) it had to be a prospective study; 2) treatment with 
morphine, oxycodone, fentanyl, methadone, or hydromorphone for cancer-related pain 
was required; 3) patients had to be naive for these opioids before inclusion in the study; 
4) data on specific side effects (constipation, nausea, vomiting, delirium, hallucinations, 
myoclonus, sweating, drowsiness, and/or dry mouth) were given; and 5) only full-text 
articles published in English, German, Dutch, or French were considered. When the same 
cohort of patients was described in multiple articles, the article describing the largest 
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cohort or fulfilling our inclusion criteria best was chosen, provided that no information on 
adverse events (AEs) was lost.
For studies fulfilling our inclusion criteria, data were extracted independently by 2 authors 
(A.W.O., W.H.O.), after which extracted data were compared. Disagreements were resolved 
by discussion between the 2 reviewers. When necessary, a third reviewer (C.C.D.R.) decided.
All studies were assessed in a standardized manner. For each trial included, information 
was extracted on study design, number of patients who fulfilled the inclusion criteria, 
opioid treatment (type, route of administration, dosing, and titration), previous analgesic 
treatment, length of follow-up and loss to follow-up, AE (types of AEs, severity grade of 
AEs, method and frequency of assessment, number of patients with AEs), and confounding 
factors (eg, comedication, type of rescue medication, antitumor treatment). For studies 
including a wider group of patients than defined, only data for the patients fulfilling 
the inclusion criteria were reported. Opioid doses were recalculated to the median 
morphine equivalent daily dose (MEDD) (mg/d) according to published equianalgesic dose 
tables: oral morphine 60 mg/d = parenteral morphine 20 mg/d = transdermal fentanyl 
25 µg/h = oral oxycodone 40 mg (6). For oral methadone, we used a dose conversion ratio 
of 1:4 (methadone/morphine) (13).
Data on the specific AEs were reported as the percentages of patients with the respective 
AE. For studies that did not report on the number or percentage of patients with AEs or 
when there were uncertainties about the data, the corresponding author was contacted 
with a request for additional information. When available, data on AEs during the first week 
of treatment with the opioid were used. When AEs were given on multiple days during the 
first week, we used the highest percentage. We aimed to study the percentages of mild AEs 
and the percentages of moderate to severe AEs separately.
Results 
The literature search provided a total of 7,077 citations. Figure 1 shows the selection 
process. Thirty-six studies fulfilled our inclusion criteria. In 10 of these studies, data on 
the number of patients with AEs could not be extracted because they reported the mean/
median AE severity scores or the proportion of days with AEs only. After contacting the 
authors of these articles, data on the number of patients with AEs were supplied for 5 of 
these 10 studies. After excluding 6 more studies for various reasons (Figure 1), 25 studies 
(9 RCTs and 16 cohort studies) describing 31 treatment cohorts with different opioids 
were included in our analysis (14-38). An overview of included studies is given in Table 1. 
Thirteen studies reported on morphine, 9 on fentanyl, 6 on oxycodone, and 3, all from the 
same investigator, on methadone. No studies with hydromorphone were included.
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Most studies reported data for nausea and constipation. Vomiting, drowsiness, and dry 
mouth were reported less frequently, and just a few studies reported data on confusion, 
sweating, or pruritus. None of the studies reported on hallucinations or myoclonus 
(Table 1). For only a few studies, the occurrence rates per severity grade (mild, moderate 
to severe) of some AEs were available (18-20, 22, 23, 31, 32). We decided to pool all 
grades because data were insufficient for a comparison of mild versus moderate to 
severe AEs.
Because the included studies were found to be very heterogeneous, Table 2 gives an 
overview of study characteristics relevant for interpreting the reported occurrence rates 
of AEs. The first characteristic is pretreatment with weak-acting (WHO step 2) opioids, 
which was allowed in 7 studies (14-16, 22, 29, 32, 34), was an inclusion criterion in 
6 studies (19, 20, 23, 27, 35, 36), was not allowed in 6 studies (17, 18, 21, 28, 30, 33) and 
Figure 1. CONSORT diagram of the literature search and selection process.
Literature search up until March 27th 2015 
Pubmed, Embase, Web of Science
Search results combined N= 7077 
After adjusting for duplicates N = 5119
Additional search of references (n=7)
 Requested full text (n=323)
Examined full text and inclusion criteria applied 
(n=315)
Fullled inclusion criteria (n=36)
Included in this review (n=25)
Reporting on:
Morphine n=13
Fentanyl  n=9
Oxycodone n=6
Methadone n=3
Hydromorphone n=0
Discarded based on title or abstract, clearly did 
not meet inclusion criteria (n= 4803)
Not available in Dutch library (n=8) 
Excluded (n=279) Reasons: Other language 
(n=41) Not  opioid naive (n=163), not 
prospective (n=12), AE’s not reported (n=28), 
no cancer pain (n=16), other publication type 
(n=19)
Excluded (n=11) Cross over design (n=2) No data 
N or % pts with AE’s (n=5), entire cohort treated 
with chemo-radiation (n=1), Step II opioids 
continued (n=1), multiple papers describing 
same data (n=2)
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was unreported in another 6 studies (24-26, 31, 37, 38). The second characteristic is the 
starting dose of treatment and subsequent titration rate (shown as dose after titration 
and days needed for titration), for which sometimes large differences were seen. 
The median MEDD at the start was 60 mg, which was also the highest starting dose. 
In 5 oxycodone studies, substantially lower doses were given at the start (range in 
MEDD = 15-30 mg) but also after titration (range in MEDD = 25-48.6 mg). In 1 oxycodone 
study, the starting dose was unknown, but doses after titration were high (MEDD = 198 mg) 
(37). In 7 of 9 fentanyl cohorts, the MEDD at the start was 60 mg, and in all 3 methadone 
cohorts, the starting dose was close to 60 mg. The largest variation in treatment doses 
was seen between the morphine cohorts. The third characteristic is differences in the 
reporting and the assessment of AEs. Because there was no uniformity in the description 
of how the AEs were measured, we cited the described methods from each study briefly. 
In 1 study, AEs were reported only on day 28 (23), and 6 studies reported AEs over the 
entire follow-up period (range = 14 days to 3 months) (15, 18, 25, 34, 35, 37). For all other 
studies, except 1 with unknown time of follow-up and reporting(38), AEs were available 
for the first 3 to 10 days of treatment.
We could not include information about comedication and concurrent treatments in 
Table 2 because of limited data. In some studies antiemetics (23), laxatives (15), or both (16) 
were given as standard, and 1 study (21) recommended the use of both. In other studies, 
comedication was given as clinically indicated (18, 25, 27, 29, 32, 35, 38, 39). One study (33) 
examined the combination of oxycodone with or without the antiemetic prochlorperazine. 
For the other studies, no data on comedication/adjuvants were reported. Four studies (19, 
20, 29, 36) reported the number of patients treated with chemotherapy, radiotherapy, or 
both during the study period. 
Figure 2 shows the percentage of patients experiencing any grade of nausea, constipation, 
drowsiness, and dry mouth per study and per type of opioid (red dots, morphine; green, 
oxycodone; blue, fentanyl; and black, methadone). Each dot represents a treatment 
cohort of patients treated with a specific type of opioid, and therefore the included 
studies can be found in the figures more than once if they reported on multiple treatment 
cohorts. The studies are arranged from left to right in ascending opioid starting doses 
and, in case of similar starting doses, doses after titration. A solid black ring around a 
dot signifies that only AEs ascribed to the studied opioid were reported (14, 21, 30, 31, 
34, 35), whereas a spotted black ring around a dot signifies that this was likely the case 
but could not be determined for certain based on the information provided (29, 33, 36). 
Studies reporting all AEs regardless of causality with the studied opioid are not circled. 
In the following section, we describe the information gathered per type of AE, which is 
summarized in Figure 2.
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Figure 2.  Incidence rates of nausea, dry mouth, constipation, and drowsiness as the percent-
age of patients with any grade of the AE per study. Studies are arranged per type of opioid 
and in ascending order of treatment doses (starting and/or doses after titration). For studies 
reporting only AEs ascribed to treatment, the dots are circled with a solid black ring or a spot-
ted black ring (probably reporting only AEs ascribed to treatment).
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Nausea
As shown in Figure 2, the reported rates of occurrence of nausea varied from 3 to 85 % 
(16, 25). In all treatment cohorts in which only AEs ascribed to the opioid were reported, 
the occurrence of nausea was ≤50%, whereas in 8 of 20 cohorts reporting all AEs, rates 
above 50% were reported. Remarkably low rates were reported in the study by Harris et 
al (16), who reported nausea in 3.5% of patients but vomiting in 14.5%. Because studies 
are arranged in ascending starting/titration doses from left to right, we see a trend in 
the morphine studies (red dots) showing higher rates of nausea as treatment doses 
become higher. An exception is the study by Vijayaram et al (36), who reported a low 
rate of nausea (21.5%) despite the high morphine doses after titration. In this study, no 
systematic assessment for AEs was performed, and only AEs spontaneously reported by 
patients were registered. In the oxycodone, fentanyl, and methadone cohorts, there was 
less variation in treatment doses; we can see no trend in Figure 2 because the occurrence 
of nausea varied widely regardless of treatment doses.
At first glance, nausea seems to be less likely to occur in the oxycodone studies. However, 
low starting and titration doses were used in most of these studies (Table 2), and 3 of 
the 6 studies reported not all AEs but only AEs ascribed to oxycodone. The heterogeneity 
among the studies made comparisons between the different opioid types impossible. 
Although the rates of nausea were high in 2 of 3 methadone studies (25, 27) the rate of 
nausea was remarkably low in the third methadone study (26), although these studies 
seemed similar with respect to dose and assessment method.
Vomiting
Although vomiting was explicitly reported in fewer studies compared with nausea, in 
general, the occurrence of vomiting paralleled that of nausea (data not shown), with a 
broad range of 4-50%.(20, 30). Four studies reported nausea/vomiting as one AE (17, 27, 
36, 37) and in 3 other studies (14, 16, 29) the reported rate of vomiting was higher than 
for nausea. Based on these data, we were not able to make a comparison between the 
different opioids.
Constipation
The rate of constipation also ranged widely, from 5 to 97% (19, 36). The pattern of 
distribution of reported rates was in line with that of nausea. A dose-effect relationship 
could be seen for the morphine studies and possibly also for the fentanyl studies. The 
lowest rates were seen in the studies reporting AEs ascribed to opioid treatment (11–38%) 
and in studies in which no systematic assessment of AEs was performed and only AEs 
spontaneously reported by patients were given (5–29%) (15, 35, 36). Regarding differences 
between the types of opioids, in all fentanyl cohorts, the reported percentage of patients 
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with constipation was <50%, whereas in 6 of 13 morphine cohorts the percentage was > 
50% (19, 20, 22, 25, 28, 32). The reported rates of constipation were also low (10.5–49%) in 
the oxycodone studies, but as mentioned for nausea, treatment doses were low and 3 out 
of 6 studies reported only AEs ascribed to treatment.
Drowsiness
Drowsiness was reported for 23 treatment cohorts from 18 studies (Figure 2) and the 
rates ranged from 3 to 88% (18, 22). The rates again seemed highest in the studies with 
the highest treatment doses. The lowest rates (3–50%) were seen in studies reporting 
AEs ascribed to the opioid use (14, 21, 30, 31, 33, 34) or in studies reporting only AEs 
spontaneously reported by patients (15). Compared with the low rates of nausea and 
constipation in the oxycodone cohorts, the rate of drowsiness was relatively high in 3 of 5 
oxycodone studies (43–50%), despite the low treatment doses and the reporting of only 
treatment-related AEs in 2 of these studies (21, 30).
Dry Mouth
Dry mouth was reported in 12 treatment cohorts from 8 studies (Figure 2), and its 
occurrence varied from 1 to 94% (18, 22). Despite this huge variation, the rate was ≥48% 
(median = 68.8%) in 8 of these 12 cohorts. Three studies with low incidence rates (4.5–
15.6%) reported either AEs ascribed to the treatment or only AEs spontaneously reported 
by patients without systematic assessment (15, 26, 34). The reason for the low rate (1%) in 
the study by Kang et al (18) is unknown to us. Overall, the reported rates of dry mouth are 
high compared with the rates of the other AEs.
Other AEs
Confusion as an AE after starting opioids was reported only in studies by de Conno et al 
(14) and Mercadante et al.(25-28), and the reported rates ranged from 7 to 80% (data not 
shown). Sweating was reported in 4 studies and ranged from 5 to 66% of patients (19, 29). 
Itching was reported in 6 studies and ranged from 0-9% (24, 36) (data not shown).
We did not find lower rates of AEs in study cohorts pretreated with codeine, tramadol, or 
dextropropoxyphene compared with cohorts in which the studied opioids were started 
directly. In general, studies performed in non-Western countries (China, Korea, Iran, India, 
Nigeria, and Egypt) reported lower rates of AEs compared with studies performed in 
Western countries and Japan.
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Discussion
To our knowledge, this is the first review providing an overview of AEs after starting 
treatment with morphine, oxycodone, fentanyl, or methadone for cancer-related pain. 
In general, we found that the occurrence rates of AEs (of any grade) were high, although 
there was a broad range in reported rates of all AEs. AEs have a negative impact on quality 
of life, and the number of symptoms has been shown to be associated with heightened 
psychological distress and poorer quality of life (40). Symptoms that seem to be of 
particular impact are drowsiness and dry mouth because both have a high prevalence and 
are rated as moderate to severe by many patients (11, 41). Both symptoms have been 
shown to be ‘‘quite a bit’’ or more distressing in about 20% of patients experiencing them 
(40). Drowsiness and other central side effects (hallucinations, confusion) frequently 
contribute to opioid failure (42, 43). Our data indicated a dose-effect relation, with higher 
rates of AEs reported in studies with higher opioid starting doses and/or higher doses after 
titration, but this effect was mainly seen in the morphine cohorts because the variation 
in treatment doses was less in the studies with fentanyl, oxycodone, and methadone. 
The striking heterogeneity among included studies made it difficult to compare AEs 
between the different opioids. Despite this, the rate of constipation seemed to be lower 
for fentanyl than for morphine, a finding that has previously been reported (3-5, 44). Also, 
the rate of drowsiness was high in the oxycodone cohorts, especially given the fact that 
low oxycodone treatment doses were used, which probably explains the low rates of 
nausea and constipation in these cohorts. However, no definite conclusions can be drawn 
because despite our inclusion criteria, we were confronted with a large heterogeneity 
among the included studies, leading to broad ranges of reported rates of AEs. Differences 
in assessment of and subsequent reporting of AEs seem to be of significant influence 
on the reported rates of AEs. Studies reporting only AEs ascribed to the studied opioid 
described lower rates than studies reporting all AEs, regardless of the causality with the 
studied opioid. This is not surprising, because we know that the prevalence of symptoms 
that can be seen as side effects of opioid treatment is high in patients with cancer, 
regardless of their treatment with opioids (11, 12). Also, in studies in which no systematic 
assessment of AEs was performed and only AEs spontaneously mentioned by patients 
were reported (15, 35, 36), low occurrence rates were found, especially for constipation 
and dry mouth. We can speculate that patients mention these AEs less freely than other 
AEs when no direct assessment is used. Contrary to what we assumed and experience in 
clinical practice, we could not identify a protective effect of pretreatment with codeine 
phosphate, dihydrocodeine, dextropropoxyphene, or tramadol. However, if we looked 
at individual studies in which AEs were reported separately for opioid-naive patients and 
for patients pretreated with codeine or tramadol, pretreated patients had lower rates of 
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AEs than opioid naive patients, with the exception of constipation (29, 34, 35). Therefore, 
the fact that overall rates of AE’s were not lower in pretreated versus naive patients is 
probably due to the heterogeneity between the studies. 
Our data are in line with findings from previous studies. In a meta-analysis by Reid et 
al (45) which included 4 studies, 3 comparing oral oxycodone with oral morphine and 1 
comparing oral oxycodone with oral hydromorphone, the rate of nausea ranged from 42 
to 74%, constipation from 21 to 70%, dry mouth from 33 to 74%, and drowsiness from 31 to 
90% in patients treated with oxycodone, morphine, and hydromorphone. No differences 
were found in AE profiles. A systematic review on RCTs comparing oral morphine with 
other opioids or placebo concluded that the lack of data in opioid-naive and nonselected 
populations limited the ability to draw conclusions. However, similar patterns of side 
effects were seen for morphine, oxycodone, and hydromorphone (46). A recently 
published RCT in opioid-naive patients also concluded that side effects between morphine 
and oxycodone did not differ (43). A meta-analysis of 3 studies comparing fentanyl with 
morphine (4) showed lower rates of AEs with fentanyl and morphine (nausea, 19–32% 
with fentanyl and 22–25% with morphine; constipation, 6–30% with fentanyl and 15–55% 
with morphine; and drowsiness, 17–25% with fentanyl and 19–52% with morphine) than 
we have found. One (32) of the three studies was also included in our review; the others 
did not meet our inclusion criteria because of pretreatment with strong-acting opioids, 
which probably explains the lower rates. In a recent Cochrane review (47) on the impact 
of morphine, fentanyl, oxycodone, or codeine on patient consciousness, appetite, and 
thirst, the reported rates of nausea ranged from 14 to 23%, vomiting from 7 to 15%, 
constipation from 17 to 30%, somnolence from 13 to 24%, and dry mouth from 3 to 
47%. This review included only RCTs, and the investigators were also confronted with 
multiple major problems with AE reporting. The authors call for ‘‘the development of 
definitions for AE’s that have a spectrum of severity or importance, and the development 
of appropriate measurement tools for recording such events to aid clinical practice and 
clinical research’. research. In 2 other recent Cochrane reviews (44, 48), the investigators 
conclude that the quality of the evidence is limited because of important risk of bias, and 
both studies call for the use of standardized outcome measures. This need was further 
supported in a study showing that the number of symptoms reported using systematic 
assessment was eightfold higher than the number of symptoms reported spontaneously 
(49). Also, low agreement has been shown between toxicity rates of chemotherapy 
reported by physicians (using common toxicity criteria) and patients (using a 4-point 
Likert scale). Lower rates were reported by physicians, supporting the use of patient 
reported outcomes (50).
A strength of our review is that we chose to include only patients naive for the opioids 
studied to minimize bias, because patients with an indication for opioid rotation form a 
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selection of patients not responding well to the previous opioid(s). This selection criterion 
meant that no studies with hydromorphone could be included, because in none of the 
studies was hydromorphone used as a first-line opioid. Because hydromorphone is a potent 
opioid, usually reserved for patients failing treatment with other types of opioids, this was 
not unexpected.
We must also acknowledge several limitations. First is our decision not to use a scale, 
checklist, or tool to assess the quality and risk of bias of selected studies. The use of such tools 
is advocated, and many exist for the assessment of randomized trials. However, we could 
not find any tools for the assessment of nonrandomized cohort studies, as were most of the 
selected studies. The GRADE (Grades of Recommendation, Assessment, Development and 
Evaluation) criteria automatically allocate observational studies as generating (very) low-
quality evidence (51). We therefore chose to systematically describe all included studies. 
Also, because AEs were seldom the primary outcome of included studies, we were not 
able to study the incidence of AEs because some studies reported all symptoms, whereas 
others reported only symptoms probably related to the opioids. We were therefore able 
to describe only the occurrence rates of side effects. Despite the large variation in study 
size, we weighed all studies equally because there were many other differences in possible 
influencing factors among the studies. Nevertheless, we made the variation in study size 
visible in Figure 2. Also, we excluded studies in which AEs were reported as changes in 
mean or median symptom intensity only, although this is probably the most reliable 
method for assessment, assuming that other causes of symptoms remain stable. Because 
these studies did not report the number of patients with AEs, we could not compare them 
with the other studies. Furthermore, the number of studies using symptom intensity scales 
was too small to make a separate comparison on the occurrence of mild versus moderate to 
severe AEs. Another limitation is the inevitable heterogeneity in patient populations. Study 
populations differed in patient characteristics (ie, tumor type, gender, race, body weight) 
and concurrent treatments (comedication, chemotherapy, and radiotherapy). However, 
data were too scarce to include these characteristics in this review.
Nausea, vomiting, constipation, drowsiness, and dry mouth are the most reported AEs 
in patients with cancer-related pain starting with morphine, oxycodone, fentanyl, or 
methadone; rates of these AEs were found to be high. There seems to be a dose-effect 
relation, with high starting doses and/or higher doses after titration leading to more side 
effects. There is a lack of well-performed clinical studies in patients with cancer-related pain 
in which a systematic assessment with validated scoring systems for AEs is used. Although 
side effects are important in daily clinical practice, data are insufficient and the true 
incidence of side effects is still unknown. Future studies should use standardized methods 
for the assessment and reporting of AEs; consensus on the use of these assessment 
methods is eagerly awaited.
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Abstract
Purpose: 
Transdermal fentanyl is effective for the treatment of moderate to severe cancer-related 
pain but is unsuitable for fast titration. In this setting, continuous subcutaneous fentanyl 
may be used. As data on the pharmacokinetics of continuous subcutaneous fentanyl are 
lacking, we studied the pharmacokinetics of subcutaneous and transdermal fentanyl. 
Furthermore, we evaluated rotations from the subcutaneous to the transdermal route. 
Methods: 
Fifty-two patients treated with subcutaneous and/or transdermal fentanyl for moderate 
to severe cancer-related pain participated. A population pharmacokinetic model was 
developed and evaluated using non-linear mixed-effects modelling. For rotations from 
subcutaneous to transdermal fentanyl, a 1:1 dose conversion ratio was used while the 
subcutaneous infusion was continued for 12 h (with a 50% tapering after 6 h). A 6-h 
scheme with 50% tapering after 3 h was simulated using the final model.
Results: 
A one-compartment model with first-order elimination and separate first-order absorption 
processes for each route adequately described the data. The estimated apparent clearance 
of fentanyl was 49.6 L/h; the absorption rate constant for subcutaneous and transdermal 
fentanyl was 0.0358 and 0.0135 h-1, respectively. Moderate to large inter-individual and 
inter-occasion variability was found. Around rotation from subcutaneous to transdermal 
fentanyl, measured and simulated plasma fentanyl concentrations rose and increasing 
side effects were observed.
Conclusions: 
We describe the pharmacokinetics of subcutaneous and transdermal fentanyl in one 
patient cohort and report several findings that are relevant for clinical practice. Further 
research is warranted to study the optimal scheme for rotations from the subcutaneous 
to the transdermal route. 
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Introduction
For the treatment of moderate to severe cancer-related pain, strong opioids are the 
treatment of choice (1, 2). Fentanyl is a synthetic opioid with a high affinity for the µ-opioid 
receptor and is 75-100 times more potent than morphine (3, 4). According to international 
guidelines, fentanyl is not the opioid of first choice (2), but nonetheless, it is widely used 
for the treatment of cancer-related pain. Fentanyl is recommended in patients with 
renal failure (2). Furthermore, because the incidence of constipation is lower in fentanyl 
compared to morphine (5-7) and it can be administered through a patch, it is a popular 
drug for the treatment of cancer-related pain. Fentanyl can also be used if an opioid 
rotation is necessary after failure on another type of opioid. Its low molecular weight and 
high lipid solubility make it suitable for transdermal delivery (8). Although the first patches 
used a reservoir design carrying risks of drug leakage or abuse, currently available patches 
have a matrix design. They release fentanyl at a proposed rate of 12.5–100 µg/h and the 
amount delivered is proportional to the surface area of the patch. As a gradient is needed 
between the patch and the skin, the patch contains more fentanyl than is released. A mean 
bioavailability of 92% (57–146%) has been reported (9). Reservoir and matrix patches 
and different types of matrix patches have been shown to have similar pharmacokinetic 
profiles (10, 11). The slow decrease in fentanyl concentrations after transdermal patch 
removal and the delay before achieving the maximum plasma concentrations (both 
reflecting slow release of fentanyl) make transdermal fentanyl (patches) unsuitable for 
fast titration in patients with severe pain. In this setting, parenteral titration is therefore 
preferred. Subcutaneous administration has been proven to be safe and effective (12, 13) 
and has advantages over the intravenous route as no vascular access is needed, making it 
easier to change sites and avoiding complications associated with indwelling intravenous 
catheters. In addition, subcutaneous administration can also be applied safely in an out-
of-hospital-setting (14).
In our cancer institute, patients with severe pain are preferably titrated with continuous 
subcutaneous opioids, and in this setting, fentanyl is frequently used. However, little is 
known about the pharmacokinetics of subcutaneously (sc) administered fentanyl as 
opposed to the transdermal (td) route. As part of a larger prospective pharmacologic opioid 
project, we studied the pharmacokinetics of fentanyl in hospitalized cancer patients with 
moderate to severe cancer-related pain. The purpose was to study the pharmacokinetics 
of fentanyl administered via the subcutaneous and transdermal routes to cancer patients. 
A second aim was to evaluate rotations from the subcutaneous to the transdermal route.
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Patients, materials and methods
Between January 2010 and November 2013, patients admitted to the Erasmus MC Cancer 
Institute (Rotterdam, The Netherlands) and treated with fentanyl for moderate to severe 
cancer-related nociceptive pain were asked to participate in the study. Fentanyl Sandoz® 
Matrix patches were used in available doses of 12/25/50/75/100 µg/h and patches could be 
combined. Patches were applied to the chest wall or upper arm and were replaced every 72 
h. The starting dose in opioid-naive patients was 12 µg/h and doses in other patients were 
based on previous treatment. In case of severe pain, patients were titrated by continuous 
sc infusion with the possibility of an extra bolus every hour. The dose of the bolus usually 
parallels the dose given per hour. Doses were titrated based on clinical effects. When pain 
control was reached and doses were stabilized, patients could be rotated to fentanyl (td) 
patches depending on the clinical setting. For the rotation of sc to td fentanyl, a 1:1 dose 
conversion ratio was used, based on data from previous studies (15, 16). After applying the 
patch, the sc administration was continued in the same dose for 6 h, after which 50% of the 
dose was given during an extra 6 h (17). After 12 h of patch application, the sc administration 
was stopped. Patients treated with a patch were prescribed medication for the treatment 
of breakthrough pain, mostly oral morphine or oxycodone in an immediate release 
formulation but not rapid onset opioids. For all patients, co-medication was screened for 
the concurrent use of strong CYP3A4 inhibitors or inducers. Also, liver function was checked 
based on the laboratory values of bilirubin, alanine aminotranferase (ALT), aspartate 
aminotransferase (AST) and albumin. The study was approved by the medical ethics review 
board (MEC 09.332) and conducted in accordance with the Declaration of Helsinki. Written 
informed consent was obtained from all participants. The trial was registered in the Dutch 
Trial Register (Trial registration ID: NTR4369).
Pharmacokinetic sample collection
Patients were included in the study as soon as possible after admission to the ward or 
after the start of fentanyl. Blood samples for pharmacokinetic analysis were taken during 
a maximum of 72 h after the start of fentanyl and after each change in the opioid regimen 
(dose, route of administration). The protocol prescribed sampling twice a day, around 8 
am and 8 pm, a baseline plasma sample before every change in the regimen and a series 
of samples maximally once a day around the administration of an extra subcutaneous 
bolus at baseline, 5, 15, 30 and 60 min after administration. Samples were collected using 
potassium EDTA tubes. After centrifugation of the tube, the supernatant was collected 
and stored at 70 °C until analysis at the laboratory of Translational Pharmacology (Erasmus 
MC Cancer Institute). 
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Measurements of fentanyl plasma concentrations
Fentanyl in plasma was quantitated using a validated UPLC-MS/MS method consisting of 
a Waters Acquity UPLC sample manager coupled to a triple quadruple mass spectrometer 
operating in the multiple reaction monitoring mode (MRM) with positive ion electrospray 
ionization (Waters, Etten-Leur, The Netherlands). The multiple reaction monitoring 
transitions was set at 337 → 188 for fentanyl and 342 → 188 for the internal standard 
fentanyl-d5.
Chromatographic separations were achieved on an Acquity UPLC® BEH C18 1.7 µm 2.1 x 
100 mm column thermostated at T=50 °C. A gradient at a flow rate of 0.350 mL/min was 
achieved with mobile phase A, composed of 2 mM ammonium formate and 0.1% formic 
acid, and mobile phase B, composed of methanol with 0.1% formic acid. A linear gradient 
was used, with 90% mobile phase A from 0-0.50 min followed by 90–0% mobile phase A, 
from 0.50 to 2 min, holding on 0% mobile phase A (i.e. 100% mobile phase B) for 2 min. 
This was succeeded by a linear gradient back to 90% mobile phase A from 4.0 to 4.1 min, 
which was held for 1.9 min to re-equilibrate. The overall cycle time of the method was 6 
min. The calibration curves were linear over the range of 0.100 to 10.0 ng/mL with the 
lower limit of quantitation validated at 0.100 ng/mL for fentanyl. The extraction of 200 
µL of plasma involved a deproteinization step with 100 µL of internal standard solution 
in acetonitrile and 100 µL of acetone followed by a simple liquid–liquid extraction with 
1-mL ethyl acetate after the addition of 100 µL of 4% ammonium hydroxide. For fentanyl 
(linear calibration range 0.100–10.0 ng/mL), the within- and between-run precisions at 
five tested concentrations, including the lower limit of quantitation (LLQ), were ≤5.52 
and ≤6.12%, respectively, while the average accuracy ranged from 88.5 to 94.0%. No 
adsorption of fentanyl was observed to the sampling and/or storing tubes. The inter-day 
coefficient of variation (CV) at five tested concentrations, including the LLQ, were ≤7.5% 
in individual validation runs.
Population pharmacokinetic model for fentanyl 
The analysis of log-transformed concentration–time data was carried out with non-linear 
mixed-effects modelling in NONMEM (version 7.3; Icon Development Solutions, Hanover, 
MD) by means of the first-order conditional estimation method with or without eta-epsilon 
interaction (18). Model building was assisted by Perl-speaks-NONMEM (PsN version 4.2.0, 
http://psn.sourceforge.net/) (19, 20) and the graphical evaluation with R (version 3.0.3, 
http://www.r-project.org/) and Xpose (version 4.4.1, http://xpose.sourceforge.net/) (21).
As a starting point, a one-compartment model with first-order absorption preceded by a 
lag time was used. Several model components were evaluated, including one- versus two-
compartment disposition models, alternative absorption models following transdermal 
administration (first- versus zero-order), differences between the two administration 
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routes in absorption parameters, i.e. absorption rate constant (ka) and lag time (tlag), and 
inclusion of allometrically scaled body weight on disposition parameters. Concentrations 
below the lower limit of quantification comprised less than 1% of the data and were 
discarded from the analysis. 
Inter-individual variability (IIV) in pharmacokinetic parameters was modelled using log-
normal models. An occasion was defined as a transdermal dose followed by at least one 
observation, and inter-occasion variability (IOV) was evaluated on absorption parameters 
as proposed by Karlsson and Sheiner (22):
P
ik
 = P · e ηi + κik
where Pik represents the parameter P for the ith individual on occasion k, P is the typical 
parameter for the studied population, ηi is the patient-specific random effect describing 
the discrepancy between the typical and individual parameter and κik is the random effect 
accounting for the IOV. ηi and κik are assumed to be normally distributed with mean zero 
and estimated variance w2 and p2, respectively.
Alternative residual error models were evaluated, including homoscedastic or hetero-
scedastic residual errors as well as a model combining both types of error.
Model evaluation
The selection between alternative models during the modelling process was based on 
scientific plausibility and statistical significance. Statistical evaluation comprised the 
analysis of goodness-of-fit plots, precision of parameter estimates, condition number and 
the likelihood ratio test based on the change of the objective function value (OFV). The 
OFV is given by minus twice the log likelihood, and a difference in OFV (ΔOFV) between 
nested models is approximately χ2 distributed. A ΔOFV of 3.84, 6.64 and 10.8 corresponds 
to p values of 0.05, 0.01 and 0.001, respectively, when one parameter is added to the 
model (1 df). The Akaike information criterion (AIC) was used to compare non-hierarchical 
models. The magnitude of η- and ε- shrinkage was computed according to Karlsson and 
Savic (23) to judge the reliability of various diagnostic plots. The uncertainty of parameter 
estimates was assessed using the non-parametric bootstrap procedure in PsN (1000 
bootstrap datasets). The predictive performance of the final model was evaluated with a 
population prediction-corrected visual predictive check (pcVPC) through 1000 simulations 
of the dataset (24).
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Results
Patients
Plasma samples for pharmacokinetic analysis were available for 52 patients (Table 1). 
Three patients participated in the study twice. Treatment with td and sc fentanyl in relation 
to the observations for all patients is shown in Supplemental figure 1. In 13 patients, 
samples were available during sc treatment without previous td administration; in 
9 patients, samples were available during treatment with td fentanyl without previous or 
concurrent sc treatment, and in 32 patients, samples were available during treatment with 
sc or td fentanyl, but the other treatment route was given until shortly before sampling 
(semi-simultaneous treatment) or simultaneously. The majority of patients (n=33) already 
used transdermal fentanyl before admission. In total, 942 fentanyl plasma samples were 
Table 1. Patient characteristics
Characteristics (n=52) No. (%)
Median age (years) – range 63 (23-80)
Sex
  Male
  Female
33 (63)
19 (37)
Race
  Caucasian
  Other
  Unknown
47 (90)
1 (2)
4 (8)
WHO performance status
  0
  1
  2
  3
 Unknown
0
19 (37)
17 (33)
4 (8)
12 (23)
Median body mass index –range 25 (18-40)
Median NRS in rest at start of fentanyl or on admission – range 5 (2-10)
Primary tumour localization
 Breast             
 Colorectal      
 Prostate            
 Soft tissue sarcoma/GIST        
 Urinary tract (including the kidney)    
 Other                 
8 (15)
5 (10)
7 (13)
6 (12)
8 (15)
18 (35)
Median albumin – range 39 (29-49)
Median AST (U/l) – range 31 (13-216)
Median ALT (U/l) – range 22 (7-131)
Median total bilirubin (umol/L) - range 7 (3-16)
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available with a median of 15 sparse samples per patient (range 1-86) and a median 
concentration of 1.33 ng/mL (range 0.122–10.7 ng/mL). One patient used a strong CYP3A4 
inducer –– carbamazepine 200 mg –– during his study period. In none of the patients, the 
combination of AST and/or ALT above upper limit of normal (ULN), bilirubin above ULN 
and albumin below lower limit of normal was found, and therefore it was concluded that 
none of the patients had liver failure. Doses for the transdermal route varied from 12 to 
400 µg/h (median 50 μg/h), and doses for the continuous subcutaneous infusion ranged 
from 10 to 300 μg/h (median 75 μg/h).
Fentanyl pharmacokinetics 
The pharmacokinetics of fentanyl-administered sc and td were best described by a one-
compartment model with first-order elimination and separate first-order absorption 
processes for each route. The residual error was most adequately described by a 
heteroscedastic model parameterised as an additive model on the log-scale. Due to the 
sparse sampling design, we were unable to estimate all model parameters satisfactorily, 
particularly with respect to parameters describing the absorption part. Hence, the 
apparent volume of distribution (V/F) was fixed to 280 L (25). A sensitivity analysis carried 
out with values of V/F ±50% fixed in 10% increments showed the model to be insensitive 
to the value and other parameter estimates to be stable within the tested range, with 
only t
lag 
and ka,sc varying slightly (less than ±25% deviation from the final PK parameter 
values). Inclusion of allometrically scaled body weight on CL/F and V/F was found to 
explain some variability and was kept to increase model stability. The final population 
model parameters including bootstrap results are presented in Table 2.
The estimated population value for CL/F in a 70-kg subject was 49.6 L/h. The estimation 
of a t
lag
 for td administration led to an improvement of the model fit (p value <0.001) 
with the final value of 4.73 h. In contrast, the inclusion of a tlag was not relevant for sc 
administration. The model was compared with a model with zero-order absorption for td 
fentanyl, and the AIC was clearly in favour of the first-order absorption (AIC more than 
60 points lower). The estimated absorption rate constant for subcutaneous fentanyl was 
0.0358 h-1 and for transdermal fentanyl 0.0135 h-1.
IIV was included on k
a
 for both routes (93.5 and 42.4 % for sc and td, respectively), td 
bioavailability and apparent clearance (CL/F). Bioavailability of td fentanyl was allowed to 
differ between individuals with an estimated variability of 42.3%. IOV on td ka resulted in 
a significant improvement of the model (p < 0.01) with an estimated value of 32.8 %. The 
consequence for rate and extent of absorption following td administration, given these 
characteristics, is illustrated in Figure 1.
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Table 2: Typical population pharmacokinetic parameter estimates for subcutaneous and 
transdermal fentanyl and bootstrap analysis results
Parameter (units) NONMEM       (%RSE)
estimate 
Bootstrap             (95% CI)a
mean 
Structural model parameters
  ka subcutaneous (h
-1) 0.0358 (24.4) 0.0374 (0.0248, 0.0555)
 tlag transdermal (h) 4.73 (21.2) 4.65 (2.25, 6.98)
  ka transdermal (h
-1) 0.0135 (16.8) 0.0140 (0.0105, 0.0188)
  V70kg/F (L)
 b 280 (fix) -
  CL70kg /F (L.h
-1) c 49.6 (9.36) 50.4 (40.9, 61.6)
Inter-individual variability (%CV)
 ka subcutaneous 93.5 (15.2
d) 91.1 (59.6, 119)
 F transdermal 42.3 (30.0d) 45.7 (19.7, 67.8)
 ka transdermal 42.4 (23.9
d) 41.4 (10.5, 59.2)
  CL/F 43.2 (15.2d) 41.6 (27.1, 53.9)
Inter-occasion variability (%CV)
 ka transdermal 32.8 (51.1
d) 39.2 (12.0, 77.0)
 Residual unexplained variability (%CV)
  Proportional residual error 23.4 (5.17e) 23.2 (20.6, 25.6)
a Mean and 95 % bootstrap percentile confidence intervals. Runs with estimates near a 
boundary (n = 150), rounding errors (n = 165) or crashed (n = 3) were skipped when calculating 
results.
b V
70kg
 /F= 280 x (WT/70)
c CL
70kg 
/F= estimate x (WT/70)0.75
d %RSE is reported on the approximate standard deviation scale (standard error/variance es-
timate)/2. η-shrinkage for inter-subject variability ranged between 14.6-48.4% and η-shrink-
age for inter-occasion variability was >35%
e ε-shrinkage was 5.97%. 
f The condition number of the final model was 24.99.
CI, confidence interval; CL70kg/F, apparent clearance for a subject with 70 kg; %CV, percent co-
efficient of variation, reported as sqrt(variance) x 100%; F bioavailability; ka, absorption rate 
constant; %RSE, relative standard error; tlag, absorption lag time; V70kg/F, apparent volume of 
distribution for a subject with 70 kg; WT, weight (kg).
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The model was found to describe the observed concentrations well (Figure 2). The 
performance of the model to predict median concentrations was good as illustrated by a 
pcVPC shown in Figure 3. Additional goodness-of-fit plots can be found in Supplemental 
data. 
Evaluation of rotations from subcutaneous to transdermal fentanyl 
For 14 patients, multiple plasma samples were available shortly before and after rotation 
from sc to td fentanyl using the 12 h scheme. In 12 of these patients, a rise in plasma 
fentanyl concentrations was seen after application of the first patch. Furthermore, the 
intensity of side effects increased in 9 patients while in 3 patients, severe fentanyl-related 
toxicity occurred, necessitating adjustment of treatment. The severe toxicity consisted of 
respiratory depression, severe drowsiness and nausea.
By using the final model, fentanyl plasma concentrations expected around and after 
rotation were predicted for a population of 52 patients through stochastic simulation. 
Figure 4 illustrates plasma fentanyl concentrations during the rotation from a sc infusion 
of 50 μg/h to a td patch with a delivery rate of 50 µg/h using the 12-h scheme. After the 
application of the td patch, the simulated median peak concentration is higher than 
the steady-state concentration of subcutaneous fentanyl. In addition, concentrations 
immediately after the end of the rotation scheme, i.e. 12 h after the application of the 
patch, are very variable with the 10th and 90th percentiles equal to 0.87 and 3.22 ng/mL 
(median value 1.68 ng/mL). Simulated fentanyl plasma concentrations using a 6-h scheme 
(26) produced similar results, and comparative plots can be found in Supplemental data.
Figure 1. Stochastic simulation of fen-
tanyl plasma concentrations versus time 
after application of a transdermal patch 
with a delivery rate of 50 µg/h in 52 pa-
tients. 
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Figure 2. Goodness-of-fit plots for the final model. Observed fentanyl plasma concentrations 
versus population predictions (left panels) and individual predictions (right panels) in normal 
(top panels) and logarithmic scale (bottom panels). The solid line represents the line of identity 
(x = y) and the dashed line represents a linear regression line.
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Figure 4. Simulated fentanyl plasma concentrations during the rotation from a subcutaneous 
infusion of 50 μg/h at steady state to a transdermal patch with a delivery rate of 50 μg/h using 
the 12-h scheme (1000 simulations of 52 subjects). Following this scheme, the subcutaneous 
administration is continued in the same dose for 6 h after applying the transdermal patch, af-
ter which 50% of the dose is given during an extra 6 h. The simulated solid line represents the 
median of the simulated data, and the shaded area represents the 80 % prediction interval. 
The vertical dashed line (schuin) represents the time of patch application. 
Figure 3. Population prediction-corrected visual predictive check for the final model for sub-
cutaneous and transdermal fentanyl. The x-axis represents the time after the first recorded 
dose of fentanyl after admission. Dots are the population predicted-corrected individual ob-
servations, and the solid and dashed lines represent the median and the 10th and 90th per-
centiles of the observed data, respectively. The shaded areas represent the simulation-based 
95% confidence interval for the simulated data percentiles. 
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Discussion
This prospective study in Caucasian cancer patients treated with fentanyl provides us with 
new insights into the pharmacokinetics of fentanyl which are relevant for clinical practice. 
Firstly, we developed a population pharmacokinetic model for sc and td fentanyl from a 
high number of sparse samples in this patient cohort. We found that a one-compartment 
model adequately describes the pharmacokinetics of sc and td fentanyl, similarly to the 
results of previous studies with td fentanyl (27, 28). We were able to distinguish inter-
individual variability between absorption and elimination pharmacokinetic parameters 
that along with inter-occasion and residual variability explain the high variability in plasma 
concentrations and possibly also clinical effects.
Similar PK models have been described following td administration previously (27, 
28). In our study, the CL/F was estimated to 49.6 L/h, which is similar to the values of 
40.8 and 42.4 L/h obtained in previous PK studies (10, 29). Furthermore, in line with 
previous models, the absorption from td patches over 72 h was found to be closer to a 
first-order than to a zero-order process, with a potential to lead to fluctuations in plasma 
concentrations during treatment. Indeed, fluctuation in plasma concentrations has been 
reported in several studies (30-33); however the clinical relevance of this finding was never 
widely acknowledged. In clinical practice, however, many patients report either lower pain 
scores and/or more side effects after patch change, and on the other hand, worsening of 
pain during the third day, a patch is used (16, 34).
The estimated absorption rate constant and absorption lag time are in agreement with 
the values found by Bista et al. (28) (0.013 h-1, ka) and Kokubun et al. (27) (0.0145 h
-1 and 4.93, 
k
a 
and lag time) for td fentanyl. Such slow absorption relative to elimination (absorption 
and elimination half-lives 51.3 h and 3.91 h, respectively) results in that the decline in 
plasma concentrations after achieving the peak following transdermal administration 
reflects absorption rather than elimination. The tmax predicted by our model in a typical 
patient was about 20.5 h after the administration of a patch. This value is known to vary 
substantially between patients and values in the range 12–48h have been reported (35). 
The td absorption with large variability is illustrated in Figure 1.
For sc fentanyl, published PK data are limited. In the only other study in patients treated 
with continuous infusion of sc fentanyl, only one plasma sample was taken showing 
considerable variability, but no PK parameters were presented (36). Capper et al. (37) 
described the pharmacokinetics of fentanyl after a bolus of 200 μg fentanyl sc in nine 
healthy volunteers and reported a CL/F of 53.7 L/h, similar to our estimate, and a rapid 
absorption (tmax 10–30 min). We found a slow absorption with substantial IIV in a situation 
in which fentanyl dosages were titrated using continuous infusion with extra boluses as 
needed for pain control. The estimation of a separate ka following sc boluses was tested 
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but not supported by the data. In addition, the model was evaluated with a fast absorption 
process following sc administration by fixing ka for this route (2 h-1). However, goodness-
of-fit plots and the fit of the model was statistically significantly worse (p < 0.001). In four 
patients in our study, plasma samples were available after stopping sc fentanyl because of 
rotation to another type of opioid. In all, a slow decrease in fentanyl plasma concentrations 
was noticeable which supports our data. It may be that also after subcutaneous treatment, 
some subcutaneous dose depot is formed, as has been reported for td fentanyl (9), but 
there are no firm data following sc infusion. Thus, our model describes sc infusion data, 
but mechanistic conclusions should not be drawn. However, if the absorption would be 
that slow, it suggests that continuous fentanyl is less suitable for fast titration. 
High to moderate variability in PK parameters and plasma concentrations has been 
reported before for td fentanyl, but literature on sc fentanyl is scarce. Kokubun et al. and 
Bista et al. (28) estimated moderate IIV on CL/F to 43.5 and 38.5%, respectively, following 
td patches. Although there are differences in patch type (reservoir versus matrix) and study 
populations, i.e. regarding the amount of sc fat/body mass index and hepatic metabolism, 
IIV was in agreement with our estimate of 43.2%. The IIV on ka in the study of Kokubun 
was substantially greater (71.9 %) than the 42.4 % we obtained, but we also found different 
occasions as a significant source of variability (IOV, 32.8 %). Other studies have reported 
substantial variation in bioavailability (range 60 to 97 %), in the measured rate of absorption 
(e.g. 12.5 to 60.4 µg/h with a patch of 50 µg/h) (29) and in inter- and intra-subject variability 
in plasma fentanyl concentrations (50.7 and 34.4 %, respectively) (30).
Lastly, this is to our knowledge the first evaluation of rotations from sc to td fentanyl, using 
the scheme described by Kornick et al. (17) who studied rotations from the intravenous (iv) 
to the transdermal route. More recently, a scheme using a two-step taper of iv fentanyl 
in 6 h was found to be safer than the 12-h method (26). In a PK study by the same group, 
using the 6-h scheme, a rise in plasma concentrations was seen after 3 h but without 
adverse effects (38). According to the current study, the use of the 12-h scheme, and a 
1:1 dose conversion may lead to a rather steep rise in plasma concentrations for some 
patients and clinically evident toxicity. Based on the final model, we simulated rotations 
using the 6-h scheme. This scheme may also lead to a rise in plasma levels and therefore 
potential toxicity. This is probably caused by the fact that plasma concentrations fall 
slower after stopping a sc administration than after an iv administration and by the finding 
that absorption following td administration appears to follow a first-order process. For 
confirmation of our findings, we have planned a prospective pharmacokinetic evaluation 
study of different rotation schemes without overlap of routes and with or without dose 
reduction of the first patch.
Strengths of our study are the longitudinal data that we assembled in one patient cohort 
and the large number of samples available for PK analysis. One limitation in our study 
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was that, although we were able to estimate IIV and IOV variability in PK parameters, due 
to a limited sample size, we did not investigate possible sources of variability through 
covariate modelling. Furthermore, due to semi-simultaneous administration following 
different routes of administration, the observed concentrations were the sum of those 
obtained following each route. Especially, many patients started on sc fentanyl after 
hospital admission while they already used fentanyl td at home, and sc bolus injections 
for rescue were frequently administered over the full study period. Although the semi-
simultaneous administration was accounted for in modelling, the study design was not 
optimal for modelling purposes.
In conclusion, this study describes the pharmacokinetics of sc and td fentanyl in one patient 
cohort. Findings relevant for clinical practice are the moderate to large IIV and IOV and 
that absorption following td administration potentially may lead to fluctuations in plasma 
concentrations. Furthermore, published rotation schemes for rotations from intravenous 
to transdermal fentanyl might not be applicable on rotations from subcutaneous to 
transdermal fentanyl. 
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Supplemental material 
Figure 1. Treatment with transdermal and subcutaneous fentanyl in relation to the observa-
tions for all patients.
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Figure 2. Additional goodness-of-fit plots for the final model. Conditional weighted residuals 
versus time after the first recorded dose of fentanyl following admission (upper left panel), 
conditional weighted residuals versus population predictions (upper right panel) and abso-
lute individual weighted residuals versus individual predictions (lower left panel). The grey 
line is a tendency line.
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Figure 3. Simulated fentanyl plasma concentrations during the rotation from a subcutaneous 
(sc) infusion of 50 μg/h at steady-state to a transdermal (td) patch with a delivery rate of 50 
µg/h using the 12-hour scheme (upper panel) and the 6-hour scheme (lower panel). In the 
12-hour scheme, the sc administration is continued in the same dose for 6 hours after apply-
ing the td patch, after which 50% of the dose is given during an extra 6 hours. In the 6-hour 
scheme, the sc administration is continued in the same dose for 3 hours after applying the td 
patch, after which 50% of the dose is given during an extra 3 hours. The vertical dashed lines 
represent the start and the end of the rotation scheme. The simulated solid line represents 
the median of the simulated data and the shaded area represents the 80% prediction interval 
(1,000 simulations of 52 subjects).
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Abstract
Background & Objectives:
Oral and subcutaneous morphine is widely used for the treatment of cancer-related 
pain. However, solid pharmacokinetic data on this practice are lacking. Furthermore, it is 
largely unknown which factors contribute to the variability in clearances of morphine and 
its metabolites and whether morphine clearance is related to treatment outcome. 
Methods:
Blood samples from 49 cancer patients treated with oral and/or subcutaneous morphine 
were prospectively collected and used to develop a population pharmacokinetic model for 
morphine, morphine-3- and 6-glucuronide (M3G, M6G). The influence of age, gender, renal 
function and several polymorphisms possibly related to the PK of the three compounds 
was investigated. The relation between treatment failure and morphine and metabolite 
clearances was explored. 
Results:
A one-compartment model including an extensive first-pass effect adequately described 
the morphine and metabolites data. Estimated mean AUC ratios following oral vs. 
subcutaneous administration were: M3G/Morphine 29.7:1 vs. 11.1:1; M6G/Morphine 
5.26:1 vs. 1.95:1; M3G/M6G 5.65:1 vs. 5.70:1. Renal function was significantly correlated 
with clearance of the metabolites, which increased 0.602 L/h per every 10 mL/min/1.73 
m² increase of eGFR, reaching a plateau for eGFR > 90 mL/min/1.73 m². The clearance of 
morphine or metabolites was not found to be correlated with treatment failure. 
Conclusion: 
Influence of age, gender and PK related polymorphisms was not identified on the PK of 
morphine. Clearance of morphine or metabolites was not found to explain treatment 
outcome. However, large variations in plasma concentrations of morphine, M3G and M6G, 
support further studies on the relation between plasma concentrations and treatment 
outcome.
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Introduction
Morphine is a widely used opioid analgesic and is one of the preferred treatment options 
for the treatment of cancer-related pain (1). 
After an intravenous (iv) administration, morphine is rapidly distributed from the central 
compartment to highly perfused tissues (distribution t
1/2
= 0.9-2.5 min) and thereafter the 
plasma concentrations versus time decay in a biphasic way with a short mean terminal 
elimination half-life of 1.4-3.4 hours that is similar for intravenous, subcutaneous and 
oral administrations (2, 3). After oral administration, morphine undergoes extensive 
hepatic first-pass metabolism (2, 3). Morphine is predominantly metabolised through 
glucuronidation in the liver into the conjugates morphine-3-glucuronide (M3G; 45-55%) 
and morphine-6-glucuronide (M6G; 10-15%) (4-6). While M6G is thought to contribute to 
the analgesic effects (7-9), the effects of M3G are unclear. It has been associated with 
(central) side effects and the development of tolerance to the analgesic effects in rats (10, 
11), but direct administration to humans did not produce any clinical effects (12).
Morphine is available for different routes of administration. For fast titration in case of 
severe pain, we mainly use continuous subcutaneous administration. This has been found 
to be safe and effective (13, 14), has advantages over the intravenous route and can also 
be applied safely in an out of hospital setting (13, 15). 
Little is known about the pharmacokinetics (PK) of morphine after continuous 
subcutaneous administration in cancer patients and solid PK data after oral administration 
are also lacking. Furthermore, while substantial inter- and intra-individual variability in 
plasma concentrations of morphine, M3G and M6G has been reported after oral as well 
as subcutaneous administration (16, 17), the causes for this variability and its effects on 
clinical outcomes of treatment are incompletely understood. Although treatment with 
morphine is unsuccessful in about 30% of patients (18), it is unknown what causes these 
treatment failures. A number of clinical factors such as age and gender as well as genetic 
factors have been associated with variability in pharmacokinetics and/or dynamics of 
morphine (19-22) but data are sparse and so far only a small part of variability can be 
explained at best. 
The objectives of the current population pharmacokinetic analysis were to describe 
the pharmacokinetics and metabolic ratios of morphine, M3G and M6G following 
subcutaneous and oral administration of morphine. As a second objective, the influence 
of age, gender, renal function and polymorphisms in several PK related genes on the PK 
of morphine, M3G and M6G was investigated. Finally, the relation between outcome of 
treatment and the clearance of morphine and metabolites was explored. 
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Patients, materials and methods
Between February 2010 and March 2014, patients admitted to the Erasmus MC Cancer 
Institute (Rotterdam, the Netherlands) and treated with morphine for moderate to 
severe cancer-related nociceptive pain were asked to participate in the study. All patients 
treated with morphine were eligible, i.e. patients already treated with morphine before 
admission but also opioid naive patients or patients rotating to morphine after failure 
of treatment with another type of opioid. Morphine was available as hydrochloride-3-
water (molecular weight 375.84 mg/mmol) 10 mg/mL for parenteral administration and 
as 5-sulphate-water (molecular weight 758.83 mg/mmol) extended release (tablet 10, 
20, 60, 100 mg) and immediate release formulation (liquid 20 mg/mL or dose unit 10, 
30 mg) for oral administration. The starting dose in opioid naive patients is usually 10 
mg BID or 1 mg/hr parenterally depending on the clinical circumstances. Doses in non-
naive patients are based on previous treatments. Patients treated with a fentanyl patch 
who were prescribed immediate release oral morphine for treatment of breakthrough 
pain could also be included in the study. In case of severe pain, patients were titrated 
by continuous subcutaneous infusion with the possibility of an extra bolus every hour. 
Doses were titrated based on clinical effects. When pain control was reached and doses 
were stabilized, patients could be rotated to oral extended release (ER) morphine with 
immediate release (IR) morphine prescribed as needed, using a 1:3 dose conversion 
ratio (23). Gender, age and weight (kg) at study entry were recorded as well as baseline 
creatinine values (µmol/L). The Modification of Diet in Renal Disease (MDRD)-formula was 
used to calculate the glomerular filtration rates for all patients and values >90 mL/min/1.73 
m² were truncated.
eGFR (mL/min/1.73 m²) = 175 x (0.0113 x Scr [µmol/L])
-1.154 x age [years]
-0.203 x (0.742 if female). 
For every patient treated with long-acting or continuous morphine, the outcome of 
treatment was classified as failure or non-failure. The response was classified as failure in 
case of a rotation to another type of opioid or treatment with intrathecal opioids because 
of insufficient pain control and/or side effects or the use of palliative sedation because of 
refractory symptoms associated with opioid treatment in the dying phase. 
Pharmacokinetic sample collection
Patients were included in the study as soon as possible after hospital admission or after 
the start of morphine. Blood samples for pharmacokinetic analysis were taken during a 
maximum of 72 hours after the start of morphine and after each change in the opioid 
regimen (dose, route of administration). The protocol prescribed sampling twice a day, 
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just before the administration of oral ER morphine or around 8 am and 8 pm in case of 
continuous administration, a baseline sample before every change in the regimen and 
a series of samples maximally once a day around the administration of a subcutaneous 
bolus or oral IR formulation at baseline, 5, 15, 30 and 60 minutes after administration. 
Samples were collected using potassium EDTA tubes. After centrifugation of the tube, 
the supernatant was collected and stored at -70°C until analysis at the laboratory of 
Translational Pharmacology (Erasmus MC Cancer Institute). 
Measurements of plasma concentrations of morphine, M3G and M6G 
Morphine and its metabolites in plasma were quantitated using a validated UPLC-MS/
MS method consisting of a Waters Acquity UPLC sample manager coupled to a triple 
quadruple mass spectrometer operating in the multiple reaction monitoring mode (MRM) 
with positive ion electro spray ionization (Waters, Etten-Leur, The Netherlands). The 
multiple reaction monitoring transitions were set at 286→201 and 462→286 for morphine 
and M3G and M6G respectively.
Chromatographic separations for morphine were achieved on an Acquity UPLC® BEH 
C18 1.7 µm 2.1 x 100 mm column eluted at a flow-rate of 0.350 mL/min on a gradient of 
methanol. The overall cycle time of the method was 6 minutes. The calibration curves 
were linear over the range of 1.00 to 100 ng/mL with the lower limit of quantitation (LLQ) 
validated at 1.00 ng/mL for morphine. The within and between-run precisions at five 
tested concentrations, including the LLQ, were ≤ 10.3 and ≤ 8.67%, respectively, while the 
average accuracy ranged from 91.9 to 96.9%. The interday coefficient of variation (CV) at 
five tested concentrations, including the LLQ, was ≤ 11.8% in individual validation runs. 
The extraction of 200 µL of plasma involved a deproteinization step with acetone followed 
by a simple liquid extraction with ethyl acetate. For M3G and M6G chromatographic 
separations were achieved on a VisionHT C18-P 3 µm 2.1 x 50 mm column eluted at a flow-
rate of 0.250 mL/min on a gradient of acetonitrile. The overall cycle time of the method 
was 10 minutes. The calibration curves were linear over the range of 10.0 to 1000 ng/
mL for M3G and 2.00 to 200 ng/mL for M6G with the LLQ validated at 10.0 ng/mL for 
M3G and 2.00 ng/mL for M6G. In patients with metabolite concentrations above these 
values, samples were adequately diluted in blank human plasma prior to processing until 
the signal fell within the calibration range. The within and between-run precisions at five 
tested concentrations in human potassium EDTA plasma for M3G, including the LLQ, were 
≤ 5.16 and ≤ 2.18%, respectively, while the average accuracy ranged from 84.0 to 96.5%. 
For M6G, the within and between-run precisions at five tested concentrations, including 
the LLQ, were ≤ 16.2 and ≤ 9.12%, respectively, while the average accuracy ranged from 
87.0 to 105.5%. The interday CV at five tested concentrations, including the LLQ, were ≤ 
8.1% and ≤ 8.2% for M3G and M6G respectively in individual validation runs. The morphine 
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glucuronides were extracted from 100 µL aliquots of plasma after the addition of 850 µL 
ammonium carbonate buffer pH 8.8 followed by a solid-phase extraction using Oasis® 
HLB 1cc (30 mg) SPE columns.
SNP analysis 
Single nucleotide polymorphisms (SNPs) which have been related to morphine PK were 
studied (Table 1). DNA was isolated from 1 mL EDTA blood on the MagNA Pure LC 2.0 
instrument (Roche Diagnostics®), with further analysis performed on the 7500 Real-Time 
PCR System (Life Technologies®). Hardy-Weinberg (HW) equilibrium was calculated 
with the chi-squared – test. Additionally, the observed minor allele frequency (MAF) 
was compared with the European MAF from HapMap in dbSNP (National Center for 
Biotechnology Information). The SLC22A1 haplotype (consisting of either 2 active alleles, 
a combination of 1 active vs. 1 inactive allele or 2 inactive alleles) was estimated based on 
the expectation-maximization (EM) logarithm with R (version 3.1.1) haplo.stats package, 
using a posterior probability > 0.98. 
Population pharmacokinetic modelling 
The analysis of concentration-time data of morphine and its metabolites was conducted 
with the first-order conditional estimation method with eta-epsilon interaction through 
non-linear mixed effects modelling in NONMEM (version 7.3; Icon Development Solutions, 
Hanover, MD) (24). Model building was supported by Perl-speaks-NONMEM version 4.2.0, 
Xpose version 4.4.1 (25) and R version 3.2.0.
Concentration data and doses of morphine were expressed as free base in molar units 
(nmol/L and nmol, respectively), the latter calculated taking into account the salt 
administered. All dosing history concerning administration of morphine before and 
during the period of sampling was included in the dataset. Concentrations below the LLQ 
comprised 7.6%, 0.7% and 0.9% of the data of morphine, M3G and M6G, respectively, and 
were discarded from the analysis (26).
First, a pharmacokinetic model was developed for morphine following subcutaneous 
and oral administration, starting out from previously published models (27, 28). 
Oral bioavailability was estimated under the assumption of complete subcutaneous 
bioavailability as indicated in the current literature (29-31). Thereafter, the model 
was extended to describe also the pharmacokinetics of the metabolites. The rate of 
appearance of the metabolites was parameterized as a fraction of the rate of elimination 
of morphine, with fractions fixed to literature values (4-6). The inclusion of first-pass 
formation of metabolites following oral morphine was assessed in the model and the sum 
of the estimated fractions of morphine reaching the systemic circulation unchanged or 
undergoing first-pass metabolism to metabolites was constrained to a maximum of 1. The 
85
5
influence of age and gender on the PK profiles was explored and the relationship between 
eGFR and clearance of the metabolites was assessed. 
Inter-individual variability (IIV) in PK parameters was modelled using log-normal models. 
Homoscedastic, heteroscedastic and combined residual errors models were evaluated. 
The correlation between parent drug and metabolite concentrations from the same 
sample was taken into account utilizing the L2 data item in NONMEM.
Selection between alternative models was based on scientific plausibility, statistical 
significance, precision in parameter estimates and visual inspection of goodness-of-
fit plots. Statistical significance was determined with the likelihood ratio test using 
the NONMEM objective function value (OFV). The OFV is given by minus twice the log 
likelihood and a difference in OFV (ΔOFV) between nested models is approximately χ2 
distributed. A ΔOFV of 6.64 and 10.8 corresponds to p-values of 0.01 and 0.001, when 
one parameter is added to the model (1 df). The reliability of various diagnostic plots 
was judged based on magnitude of η- and ε- shrinkage (32). The precision of the model 
parameter estimates was obtained with the Sampling-Importance-Resampling (SIR) 
method (33). In addition to the general advantages of SIR (e.g. fast runtimes as it does not 
require estimation steps, flexibility in addressing asymmetric confidence intervals), SIR 
was deemed more appropriate than the bootstrap in this case because it is less sensitive 
to sample size and does not require stratification of the data, which is particularly 
useful with unbalanced study designs involving a few subjects. Further details on the 
Table 1. Summary of selected genetic variants
UGT2B7
•   Uridine 5’-diphospho-glucuronosyltransferase 2B7 (UGT2B7) is a phase II (glucuronidation) metabolizing enzyme encoded by the 
UGT2B7 gene.
•  UGT2B7 is involved in the conversion of morphine into M3G and M6G.
•   The G-allele of polymorphism -900G>A (rs7438135), which is in complete linkage disequilibrium (LD) with polymorphism 802C>T, 
has been associated with a decreased glucuronidation (56, 57). 
SLC22A1
•  Organic cation transporter 1 (OCT1) is encoded by the SLC22A1 gene.
•  OCT1, expressed at the sinusoidal membrane of the human liver, mediates the cellular uptake of morphine [51]. 
•  Healthy volunteers with SLC22A1 polymorphisms have reduced morphine uptake in the hepatocytes (54). 
•  Children with 2 loss-of-function SLC22A1 alleles have lower morphine clearance than carriers of the active SLC22A1 alleles (55).
ABCC3
•  ATP-binding cassette C3 (ABCC3) is an organic anion transporter encoded by the ABCC3 gene. 
•   ABCC3, expressed on the basolateral membranes of hepatocytes, mediates the efflux of M3G and mostly likely also M6G into the 
bloodstream (58). 
•  ABCC3 polymorphism -211C>T (rs4793665) was associated with a significantly altered mRNA expression (59, 60).
•  Children with the −211CC genotype had significantly higher M3G and M6G levels (~40%) than carriers of the -211T allele (55).
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SIR procedure are presented in Electronic Material (supplemental text material). The 
predictive performance of the final model was evaluated with visual predictive check (VPC) 
or population prediction-corrected VPC (pcVPC) (34) for the observed concentrations as 
well as for concentration ratios. The concentration ratios M3G:M, M6G:M and M3G:M6G 
following uniquely the subcutaneous or the oral route of administration were calculated 
by dividing the respective observed or simulated concentrations.
Influence of genetic variants and assessment of treatment failure 
After finalization of the population PK model, the influence of UGT2B7 (rs7438135), 
SLC22A1 (rs72552763, rs12208357, rs34130495, rs34059508) and ABCC3 (rs4793665) genetic 
variants were explored on total morphine clearance and morphine metabolic clearances 
to M3G and M6G; ABCC3 (rs4793665) was also studied in relation to the clearance of the 
metabolites. In addition, the model was used to assess whether failing treatment was 
related to a difference in clearance of morphine or metabolites. The influence of failing 
treatment was tested in the model as a binominal variable on the clearance of morphine 
and metabolites, not with the purpose of explaining parameter variability but to identify a 
possible association between failing the treatment and clearance.
Results
Patients
The dataset contained 410 samples from 49 patients (Table 2). Treatment with oral 
and subcutaneous morphine in relation to the observations for all patients is shown in 
supplemental figure 1 and observations in relation to time after first dose in supplemental 
figure 2. The median treatment doses were 2 mg/h for continuous and bolus subcutaneous 
morphine (ranges 0.6-14 mg/h and 0.6-10 mg), 40 mg BID for oral ER morphine (range 10-
150 mg) and 10 mg for oral IR morphine (range 5-60 mg). Creatinine values were missing 
for 4 patients and were imputed based on linear regression of the available values of eGFR 
on age and gender. In 7 patients baseline eGFR was between 30-60 mL/min/1.73 m² (range 
33-57 mL/min/1.73 m², median 43 mL/min/1.73 m²). All other patients (n=38) had an eGFR 
≥ 60mL/min/1.73 m². In twelve out of 43 patients treated with long-acting/continuous 
morphine, the outcome of treatment was classified as failure, in all due to the occurrence 
of dose limiting side effects. 
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Table 2. Baseline characteristics
Characteristics (n=49) No % or range
Median age (years) – range 60 38 - 80
Gender
   Male
   Female
27
22
55
45
Median Weight (kg) 83 53 - 140 
Body Mass Index (kg/m2)
   Underweight < 18.5
   Normal range 18.5-25
   Overweight 25-30
   Obese 30-40
   Severely obese >40 
1
13
20
13
2
2
27
41
27
4
Race
   Caucasian
   Latin-American
   Unknown/other
44
1
4
90
2
8
Median WHO Performance Status - range 2 (0 - 3)
Primary tumor localization
Breast
Colorectal
Prostate
Sarcoma
Other
11
7
6
4
21
22
14
12
8
43
Distant metastasis present 44 89 
Median creatinine (µmol/l) 72 25 - 190
Median estimated glomerular filtration rate (mL/min/1.73 m²) 81 33 - >90
Median serum albumin (g/L) 40 28-47
Routes of administration during sampling
Subcutaneous 
Oral extended and immediate release
Oral immediate release only
Both oral and subcutaneous consecutively 
28
12
6
3
57
24
12
6
UGT2B7 G>A
 - GG (wild type)
 - GA (heterozygous)
 - AA (variant)
14
26
9
29
53
20
SLC22A1
 - 2 active alleles
 - 1 active allele/1 inactive allele
 - 2 inactive alleles
26
18
5
53
37
10
ABCC3 C > T
 - CC (wild type)
 - CT (heterozygous)
 - TT (variant) 
5
28
16
10
57
33
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Figure 1. Schematic figure of the pharmacokinetic model developed to describe plasma 
concentrations of morphine and metabolites (M3G and M6G) following oral immediate-re-
lease (IR), oral extended-release (ER) and subcutaneous administration. Abbreviations: CL 
morphine clearance; CLmet metabolites clearance; F1p, met fraction of morphine converted to 
metabolites in first-pass effect; Fm, met fraction of morphine clearance forming metabolites; 
Foral oral bioavailability; ka, ER absorption rate constant for oral extended-release morphine; 
ka, IR absorption rate constant for oral immediate-release morphine; ka, SC absorption rate 
constant for subcutaneous morphine; tlag
ER
 absorption lag-time for oral extended-release 
morphine; V morphine volume of distribution; Vmet metabolites volume of distribution.
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Figure 2. Prediction- and simulation-based diagnostics for the final population pharmaco-
kinetic model. Observed concentrations of morphine, M3G and M6G vs. population 
predictions (upper panel) and observed concentrations vs. individual population predictions 
(middle panel); the solid line is a unity line and the dashed line is a linear tendency line. 
Prediction-corrected visual predictive checks (lower panel) through 1000 replications; 
dots are the predicted-correct concentrations of each entity, the solid red line represents 
the observed median and the shaded area represents the 95% confidence interval for the 
simulated median.
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Figure 4. Observed and simulated (1000 replications) metabolic concentration ratios 
(M3G:morphine, M6G:morphine and M3G:M6G) over time stratified by route of 
administration; dots are the observed metabolic concentrations ratios, the solid red line 
represents the observed median and the shaded area represents the 95% confidence interval 
for the simulated median.
Figure 3. Illustration of M3G and M6G clearance in relation to glomerular filtration rate 
(eGFR) and body weight.
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Morphine pharmacokinetics 
The pharmacokinetics of subcutaneous and oral morphine was adequately described by 
a one-compartment model with separate first-order absorption processes for each route. 
Parameters describing the absorption phases for subcutaneous and oral immediate-release 
morphine were fixed to literature values (27, 28) and the value of the absorption rate constant 
for oral extended-release morphine was estimated (p-value < 0.001 when compared to a 
fixed value of 0.8 h-1). The fractions of total morphine clearance forming M3G and M6G were 
fixed to 0.57 and 0.10, respectively (4-6).
The pharmacokinetics of M3G and M6G were appropriately described by first order 
systemic and additional first-pass formation and first order elimination according to a one-
compartment model (figure 1). Note that given the parameterisation of the model (fixed and 
estimated fractions of formation) the estimated disposition parameters reflect true, and not 
apparent, values. The inclusion of first-pass metabolism statistically significantly improved 
the fit of the parent-metabolite model (p-value < 0.001). The metabolites disposition 
parameters were estimated to common values and the estimation of separate clearance 
and volume parameters for each metabolite was not found to be statistically significant 
(p-value > 0.01). The final population model parameters for morphine, M3G and M6G are 
presented in table 3.
The model was found to fit the data well as shown by the absence of major systematic trends 
in the goodness-of-fit plots and pcVPCs (figure 2). Allometric body weight with theory-
based exponents was included a priori on all disposition parameters of all entities (35). Age 
did not statistically significantly improve the model fit (p-value > 0.01). The inclusion of 
an effect of gender on clearance of morphine resulted in a decrease of 17.0% for females 
(p-value > 0.01) but was not retained in the model. The clearance of the metabolites was 
found to change with eGFR (p-value < 0.001) and increased 0.602 L/h with every increase in 
eGFR of 10 mL/min/1.73 m² up to an eGFR of 90 mL/min/1.73 m², above which clearance was 
constant (figure 3).
The mean area under the plasma concentration-time curve (AUC) molar ratios for a typical 
patient (with 70 kg and eGFR of 81 mL/min/1.73 m2) following oral morphine compared with 
the subcutaneous route of administration for the same dose were: M3G/Morphine 29.7:1 vs. 
11.1:1; M6G/Morphine 5.26:1 vs. 1.95:1; M3G/M6G 5.65:1 vs. 5.70:1. The concentration ratios 
over time and respective model predictions by route of administration are shown in figure 4.
Influence of genetic variants
An effect of UGT2B7, SLC22A1 and ABCC3 SNPs on total clearance of morphine and 
morphine metabolic clearances to M3G or M6G could not be identified (p-value > 0.01). 
Similarly, an effect of ABCC3 genotype on the clearance of the metabolites was not found 
(p-value > 0.01). 
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Assessment of treatment failure in relation to metabolism
Differences in clearance of morphine, M3G and M6G in patients in whom treatment with 
morphine failed (n=12) compared with patients in whom treatment did not fail (n= 31) 
could not be identified (p > 0.01 in all cases).
Discussion
First, we developed a population pharmacokinetic model for morphine, M3G and M6G 
following subcutaneous and oral morphine administration from a high number of sparse 
samples. We found that a one-compartment model with separate first-order absorption 
processes for each route adequately describes the plasma concentrations of morphine 
and a one-compartment model following first-order systemic and additional first-
pass formation from morphine appropriately describes plasma concentrations of the 
metabolites. Our results are in line with literature data. 
PK data after subcutaneous administration are scarce. The basis for the morphine model 
was the model by Upton et.al.(27) who reported a CL of 79.8 L/h in a population of 22 post-
operative patients aged 50 years or over. In a study by Stuart-Harris et.al (29) in 6 healthy 
volunteers, CL of 83.1 L/h (subcutaneous bolus), 95 L/h (iv) and 127.5 L/h (subcutaneous 
infusion) were reported. In a recent publication, a lower CL of 47.5 L/h was reported in a 
slightly older and terminally ill population, with – compared to our cohort – lower serum 
albumin values (median 26 g/L), shorter survival (median 33 days) and most likely lower 
body weight (not reported), and these factors may suggest lower metabolic capacity and 
explain the lower CL in that study (36). Thus, CL in our study estimated to 92.9 L/h for a 
patient weighing 70 kg is in reasonable agreement with previous data.
Clearance for the metabolites was estimated to a common value of 4.71 L/h for a subject 
weighing 70 kg and with eGFR 81 mL/min/1.73m². The estimation of separate disposition 
parameters for M3G and M6G did not statistically significantly improve the model, 
suggesting that these entities might have the same clearance and volume of distribution, 
or that the model cannot distinguish the difference. Thus, the different PK profiles 
of the metabolites depend exclusively on the fraction of systemic (subcutaneous 
and oral) and first-pass formation (oral) of the metabolites. This is in line with the 
observed strong correlation (R2=0.963) of the metabolites, as reported in other 
studies (37, 38). Furthermore, the values of CL and V for intravenous M3G in healthy 
volunteers, 10.1 L/h and 23.1 L (39), are in agreement with previously published values 
for intravenous M6G (40, 41) and corroborate the similarity found in the disposition 
PK parameters of metabolites in our study. Furthermore, CL and V of M6G  in cancer 
patients following intravenous administration of M6G was found to be 5.8 L/h and 
96
22 L, respectively, thus in good agreement with our estimates and supporting our findings 
(42).
Concentration-time data following the administration of subcutaneous and oral morphine 
allowed the estimation of the oral morphine bioavailability (37.2%) and, in addition, the 
fractions of the oral morphine dose that undergo first-pass metabolism to M3G (35.5%) 
and M6G (6.31%). It is not expected that the fractions are in agreement with the Fm, i.e. 
the fractions of morphine clearance forming the two metabolites. The fraction of the 
dose formed into a metabolite in the first pass is dependent on several factors; whether 
metabolism occurs in the intestinal wall in addition to the liver, whether all metabolites 
are formed in the first passage (i.e. whether total clearance is equal to hepatic clearance) 
and the blood-to-plasma ratio of morphine. The values estimated are in line with only 
hepatic first pass metabolism (for all pathways) but it is not solid evidence of lack of 
intestinal wall formation.
As expected, the subcutaneous route of administration, which avoids first-pass 
metabolism, resulted in lower metabolite:morphine concentration ratios compared 
to the oral route. According to Hasselstrom et.al.(5) and supported by our data, this 
difference is due to higher morphine plasma concentrations and therefore the AUCs of 
the metabolites formed following both routes of morphine administration are similar. The 
observed and model-predicted ratio M3G:M6G remained constant regardless of level of 
renal impairment or route of administration. The clinical consequences of the differences 
in metabolite:morphine ratios are uncertain. We could only find one study comparing oral 
and subcutaneous administration using a cross-over design (23). This study reported less 
nausea and somnolence during treatment with subcutaneous morphine, a finding that we 
recognize from our daily clinical practice. The relationship between plasma concentrations 
of morphine and metabolites and clinical effects is unsure however, because some studies 
have failed to show a correlation (43-45), while others did report an association (9, 37, 46). 
Although we did not perform a full pharmacokinetic-pharmacodynamic analysis, we tried 
to identify an association between outcome of treatment and clearance of morphine. 
The outcome of treatment may not be associated with a different clearance of morphine 
and other factors may be more important in this regard. The relation between clearances 
and plasma concentrations of morphine and the metabolites and outcomes of treatment 
deserves further study. 
Secondly, in an attempt to explain variability in PK parameters, we studied the role of 
several clinical and genetic covariates on the clearances of morphine and the metabolites. 
In our study, inclusion of both age and gender did not statistically significantly improve 
the model, although we estimated a 17% lower clearance in females. Reported data on 
the effects of age, are conflicting. Age was reported to predict post-operative morphine 
requirements (47) and PK studies have reported either lower clearances and volume of 
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distribution in elderly patients (20) or higher plasma concentrations of M6G and/or M3G 
(48, 49), while others found no significant impact of age (50). A possible explanation for 
these findings is the fact that in most studies renal function – which declines with age – 
was not taken into account. However, in the study by Klepstad et.al (49), serum creatinine 
and age were found to be independent contributors to outcome in a multivariable analysis. 
Regarding gender, in a systematic review and meta-analysis, Niesters et.al (21) found that 
women display greater opioid analgesia than men and this effect was largest when the 
analysis was restricted to patient-controlled analgesia studies with morphine. It is unsure 
however, if this gender difference can be attributed to pharmacokinetic differences. 
While McQuay et.al (48), found lower plasma concentrations of morphine and M6G in 
men compared to women, the effect of gender was also non-significant in other modelling 
studies (27, 50). 
Furthermore, clearance of the metabolites was found to be a function of body weight 
and renal function (figure 3), while no correlation was found between these two (data 
not shown). The consequence of this combined finding for dose recommendation is not 
clear, and would demand to take into account the systemic exposure of morphine and 
metabolites simultaneously. Although accumulation of M3G and M6G in patients with 
impaired renal function is widely reported (51), data on the clinical effects of morphine 
treatment in these patients are scarce and conflicting. Reducing the frequency of 
administration or the dose are carefully suggested in guidelines (1, 52), but opioid rotation 
to an opioid without renally excreted active metabolites, such as fentanyl, should also be 
considered. 
We did also not identify significant effects of genetic variants in transporters (OCT1, 
ABCC3) and the phase-II metabolizing enzyme (UGT2B7) on morphine PK. Remarkably, 
almost all of the previously identified effects of these genetic variants were found in 
children and mainly in small patient populations (Table 1). In our adult population, we 
were unable to confirm previously identified effects. This may be caused by lower rates 
of glucuronidation in children and possibly overcapacity in adult livers. Additionally, the 
absence of a genotypic OCT1 effect could be due to construction of the OCT1 haplotype 
in the current study. Recently, a study addressing worldwide genetic variability within this 
gene and assessing the effect of several genetic variants (a.o. SLC22A1*2-*6 alleles) on 
10 probe compounds, found that the effect of the *2 allele on the transport function is 
substrate dependent (53). This makes the *2 allele rather a reduced function allele against 
morphine than total loss-of-function, as previously suggested (54, 55). 
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Conclusions
We found that a one-compartment model adequately described the pharmacokinetics 
of morphine after subcutaneous and oral administration and a one-compartment 
model following first-order systemic and additional first-pass formation from morphine 
appropriately described the plasma concentrations of the metabolites. The estimated 
relative bioavailability of 37.2% for oral morphine confirms the dose conversion ratio of 
1:3 when converting subcutaneous to oral morphine. Age and gender did not significantly 
influence the clearance of morphine, while the clearance of the metabolites was found 
to be a function of body weight and glomerular filtration rate. We found no significant 
effects of polymorphisms in UGT2B7, SLC22A1 and ABCC3 and no difference in morphine 
and metabolite clearance between patients in whom treatment failed vs patients in whom 
treatment did not fail. Further research is therefore needed to explain the variability in 
treatment doses as well as clinical outcomes.
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Figure 1. Treatment with oral and subcutaneous (SC) morphine in relation to the 
observations.
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Abstract
Aim: 
To identify clinical and genetic factors associated with outcome of opioid treatment. 
Patients & methods: 
We performed an exploratory analysis in a cohort of 353 patients treated with fentanyl, 
morphine, oxycodone, and/or hydromorphone for cancer-related pain, exploring selected 
clinical and (pharmaco-)genetic factors for a correlation with treatment failure for all and 
per type of opioid. 
Results: 
Use of adjuvant pain medication, intensity of pain at rest and age were associated with 
treatment failure in the various cohorts. Only the genetic variants rs12948783 (RHBDF2) 
and rs7016778 (OPRK1) correlated statistically significant in univariate, but not in 
multivariable analysis. 
Conclusions: 
Several clinical and genetic factors were identified that warrant further study to clarify 
their role and use in opioid treatment. 
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Introduction
Opioids are the cornerstone of treatment for moderate to severe cancer-related pain. 
Although treatment is successful in the majority of patients, 25-40% does not achieve 
sufficient pain control and/or experiences serious side effects limiting dose escalation 
(1, 2). In these cases, opioid rotation is successful in about two-thirds of patients. However, 
opioid rotation is time-consuming, which is unwanted in a population with limited life-
expectancy (3, 4). As we are currently unable to predict the clinical response to specific 
opioids for an individual patient, finding the right type and dose of opioid is still a matter 
of trial and error. The effects on pain and the occurrence of side effects are the result of a 
complex interplay between clinical / demographic, pharmacokinetic and -genetic factors 
(5, 6). So far, factors related to treatment-failure of individual opioids that can be used to 
guide treatment decisions (2, 7-10) have not been identified. 
Studies in twins, separating environmental from genetic influences, have demonstrated 
that up to 60% of the inter-individual variation in pain perception and analgesia can be 
attributed to a person’s genetic predisposition (11, 12). In the last decade, a large number 
of studies have found associations between genetic variants of drug metabolizing 
enzymes (CYP3A4, CYP2D6), membrane drug transporters (ABCB1, ABCC3, OCT1), 
molecules involved in opioid receptor signaling (OPRM1, OPRK1, OPRD1, KCNJ6) and 
pain modulators (COMT) on the one hand and opioid efficacy, required dose, and 
toxicity on the other hand (5, 13). These studies mostly had a small sample size, focused 
solely on morphine, or data from various types of opioids were pooled. The European 
Pharmacogenetic Opioid Study (EPOS) included a large number of cancer patients and 
studied the influence of genetic variability on opioid dose, during opioid treatment. 
No statistically significant associations were found between 112 single nucleotide 
polymorphisms (SNPs) in 25 candidate genes and opioid dose (14). Sub studies from the 
EPOS patient cohort focused on pharmacokinetics of fentanyl (15), pharmacokinetics of 
oxycodone (16), occurrence of nausea and vomiting (17) and constipation (18). The study 
on pharmacokinetics of fentanyl reported that the CYP3A4*22 and CYP3A5*3 variants 
accounted for a small proportion of the variability in pharmacokinetics of fentanyl (15). 
For oxycodone, CYP2D6 genotypes were shown to influence the pharmacokinetics of 
oxycodone, but not the pharmacodynamics (16). For nausea and constipation, although 
a correlation was found with 8 and 5 SNPs, respectively, only two SNPs (rs1672717 in the 
5-Hydroxytryptamine (Serotonin) Receptor 3B (HTR3B) for nausea (17); and rs2020917 
in the enzyme Catechol-O-methyltransferase (COMT) for constipation (18)) passed the 
Benjamini-Hochberg criterion for a 10% false discovery rate. However, EPOS was a cross-
sectional study, in which outcomes were studied at a random time point during opioid 
treatment. To our knowledge, no studies have assessed whether a combination of clinical 
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and genetic factors is related to the efficacy or failure of treatment with individual opioids, 
whereas this information could help to personalize pain management in cancer patients 
(19).
With the aim to identify clinical and genetic factors related to treatment failure of opioids, 
we performed an exploratory prospective study in patients treated with morphine, 
oxycodone, fentanyl, or hydromorphone for cancer-related pain.
Patients and methods
Patients admitted to the department of Medical Oncology of Erasmus MC Cancer 
Institute (Rotterdam, the Netherlands), who were treated with opioids for moderate-
severe nociceptive cancer-related pain (with or without a neuropathic component) were 
included in this prospective study. Patients with an expected duration of hospitalisation < 
72 h and patients unable to give informed consent were excluded from the study. Patients 
were admitted to our specialised acute palliative care unit (PCU) or one of two general 
oncology wards. Pain was treated stepwise following the World Health Organisation 
analgesic ladder (20) and only patients treated with strong-acting (step III) opioids were 
eligible. Treatment was given in line with our institutional protocol for the treatment of 
oncological pain, which is based on (inter-) national guidelines. Of note, because many 
patients on the PCU are admitted with complex pain problems; high doses of opioids, 
opioid rotation, parenteral administration of opioids and/or adjuvant analgesics were 
often necessary. In general, the type of opioid used before hospital admission was 
continued unless dose escalation was not possible due to side effects or problems related 
to administration. In patients with severe pain, we generally used subcutaneous morphine 
or fentanyl for titration. Doses were titrated while closely monitoring the effect on pain 
(by numeric rating scale 0-10 twice daily) and side-effects (10 most common side effects 
assessed using a 4-point Likert scale twice daily). Opioid rotation was performed in case 
of insufficient pain control despite adequate dose escalation and/or dose limiting side-
effects and/or the occurrence of other dose limiting events, such as volume related 
problems with subcutaneous infusions. Adjuvant pain medication was started in case 
of an insufficient effect of opioids in patients with mixed nociceptive-neuropathic pain. 
Selection of the opioid of first, second or third choice was based on clinical factors (i.e. 
renal function, possibility for use of oral route) and treatment history. In opioid naive 
patients, our protocol advises oxycodone as a first choice. 
Clinical and demographic data were collected. All data were registered in an electronic 
database (©2004-2012 OpenClinica, LLC and collaborators). Patients were categorised in 
treatment groups according to the type of opioid(s) they received. In case of rotations 
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between different types of opioids, patients were included in all the specific treatment 
groups. 
For the analysis, we defined T
0
 as the start of the clinical titration period for the opioid 
of study. In case of pain requiring opioid titration at admission, T0 was set at the time 
of hospitalisation irrespective of the use of opioids before referral. When an opioid was 
started after hospitalisation, T0 was set at the moment of that start. In case of an opioid 
rotation, a new titration period started. Therefore, at T0, patients could be opioid naive, 
already using the respective opioid (before hospitalisation) or starting a new opioid after 
rotation. For every patient, the treatment response per opioid was classified as failure 
or non-failure. The response was classified as failure in case of: 1) a rotation to another 
type of opioid because of insufficient pain control and/or side effects, 2) a treatment with 
intrathecal opioids because of persistent pain and/or side effects, or 3) the use of palliative 
sedation because of refractory symptoms associated with opioid treatment in the dying 
phase. In all other patients the response was classified as non-failure. A rotation from 
oxycodone to another type of opioid given parenterally was considered as failure only if the 
reason for rotation included adverse events. We excluded patients rotating solely because 
of a need for (fast) parenteral titration, as oxycodone for parenteral use is not available 
in our hospital. The study was approved by the Erasmus MC medical ethics review board 
(study ID: MEC 09.332) and conducted in accordance with the Declaration of Helsinki. The 
trial was registered at the Dutch Trial Registry (Trial registration ID: NTR4369). Written 
informed consent was obtained from all participants, with separate informed consent for 
the DNA analysis. 
Analyses of SNPs 
Blood samples for pharmacogenetic analysis were collected concurrent with the first 
venepuncture for blood sampling for a medical indication and after obtaining informed 
consent. DNA was isolated from 1 mL EDTA blood on the MagNA Pure LC 2.0 instrument 
(Roche Diagnostics®). Genetic variants were selected based on evidence from literature, 
taking into account allele frequency, clinical impact and reproducibility of effect. The 
analysis was performed with the TaqMan allelic discrimination method on the 7500 Real-
Time PCR System (Life Technologies®). CYP2D6 duplication and deletion (*5 allele) were 
determined on the ProFlexTM PCR system (Life Technologies®) and visualized via gel 
electrophoresis on 1% agarose gel.
Violation of Hardy-Weinberg (HW) equilibrium was calculated for all genetic variants 
with the chi-squared – test. Additionally, the observed minor allele frequency (MAF) was 
compared with the MAF from HapMap in dbSNP (National Center for Biotechnology 
Information). The COMT, CYP2D6 and OCT1 haplotypes were estimated based on the 
expectation-maximization (EM) logarithm with R (version 3.1.1) haplo.stats package, 
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using a posterior probability > 0.98. Patients genotyped GGC (rs4680, rs4818, rs4633 
resp.) for COMT were categorized in the low pain sensitivity (LPS) group, ACT genotype 
in average pain sensitivity (APS) group and GCC in high pain sensitivity (HPS) group, as 
previously this haplotype has been related with experimental pain sensitivity (21) and 
opioid consumption (22{Tan, 2016 #5836, 23, 24). The LPS group consisted of patients 
with the LPS/LPS or LPS/APS alleles, APS from APS/APS or LPS/HPS alleles and HPS from 
the alleles HPS/HPS or APS/HPS.
Statistical analysis
Data were analysed using STATA® version 13. Descriptive statistics were used to 
summarize patients’ characteristics. Statistical analyses were performed for the whole 
group of patients and per type of opioid. For the analysis of all patients, the first opioid 
that was used for titration during admission for which an observation period of at least 24 
hours was available, was selected. Logistic regression analysis was used with treatment 
failure as the dependent variable and the SNPs described in the previous paragraph and 
clinical/demographic factors as covariates. For the analysis in the whole group of patients 
only SNPs in genes related to pharmacodynamics or pain sensitivity were tested. The 
following clinical/demographic factors were explored: gender, age, radiotherapy on any 
tumour localisation related to the pain for which opioid treatment was initiated (either 
1-8 weeks before T0 or 1 week before - during hospitalisation), use of adjuvant pain 
medication (pregabalin, gabapentin, or amitriptyline) or use of corticosteroids started 
before T0 and continued or started on T0 or during hospitalisation, pain at rest and worst 
pain at T0 (rated using Numeric Rating Scale (NRS 0-10) and divided into categories 
mild (NRS 0-4), moderate (NRS 5-6) and severe pain (NRS 7-10) and opioid dose at T0. 
For the analysis of all patients, doses were recalculated to the median oral morphine 
equivalent daily dose (MEDD) according to published equianalgesic dose tables: oral 
morphine 60mg/d = parenteral morphine 20 mg/d = transdermal fentanyl 25 mcg/h = oral 
oxycodone 40 mg/d = parenteral hydromorphone 4 mg/d (25). For the whole group, as 
well as the opioid specific groups, doses were divided into 2, 3 or 4 equally sized dose 
level groups based on the appropriate quantiles (Q)). For the ordinal factors (pain, opioid 
dose) each category was analysed using the first category as reference. Patients already 
using opioids before admission, who were rotated within 24 hours after admission were 
excluded for the analysis of time-dependent variables for the opioid used at admission. 
Reported p-values are two-sided and because of the exploratory nature of this analysis, 
factors with a p-value < 0.10 in univariate analysis were entered into the multivariable 
analysis. The ‘backward elimination’ method was used to find the combination of clinical 
and genetic factors associated with treatment failure. Again, we used a threshold of 0.1 
for significance. Resulting p-values were not corrected for multiple testing because of the 
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exploratory nature of this analysis. The multivariable analysis was performed twice, with 
and without adjustment for opioid dose at T0. 
Results
Between January 2010 and April 2014, a total of 356 individual patients were included 
in this study. Three patients were not evaluable because they used different opioids 
simultaneously during the entire study period and therefore 353 patients were analysed. 
The median age of the patients was 61.5 years (range 24-86) and 168 (48%) patients were 
male. The most frequent tumour origins were the urinary tract (20%), gastro-intestinal 
tract (18%) and breast (16%). Most patients had advanced stages of cancer (80%) and 
the median WHO performance status was 2. The median duration of hospitalisation – and 
therefore follow-up – was 9 days (range 1-48). For all but 2 patients the duration of follow-
up exceeded 72 hours.
The majority of patients (n= 214) was treated with a single type of opioid, whereas 113 
patients were treated with 2 opioids, 22 patients with 3 and only 4 patients with 4 opioids 
(figure 1). In the fentanyl group, most patients (66%) already used fentanyl before hospital 
admission, while in the morphine group patients were mostly rotated from another type 
of opioid (58%). In the oxycodone cohort most patients were either opioid naive (38%) or 
Figure 1. A Venn diagram showing the numbers of patients treated with the specified 
opioids consecutively throughout the study. For example, 20 patients were treated with both 
morphine and oxycodone and studied in both cohorts. 
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already used oxycodone (43%) before study entry. As expected, the hydromorphone cohort 
contained mostly patients in whom treatment with other opioids had failed (89%). A wide 
range of treatment doses was observed for all types of opioids. Regarding the median 
morphine equivalent daily dose (MEDD), doses were quite similar in the fentanyl (120 mg) 
and morphine group (101 mg) but lower treatment doses were given in the oxycodone 
cohort (30 mg), whereas, as expected, MEDD was highest in the hydromorphone group 
(504 mg). The number of patients in whom treatment failed divided by the total number 
of patients per group was 104/353 (29%) for all patients, 59/233 (25%) for fentanyl, 56/163 
(34%) for morphine, 27/81 (33%) for oxycodone and 9/45 (20%) for hydromorphone.
Genotype distributions
From the total cohort, written informed consent for DNA-analysis and a blood sample 
were available for 346 patients. The undetermined genotype results ranged from 0.9-
2.3% per assessed genetic variant. None of the SNPs violated HW equilibrium (p > 0.05), 
nor were there large differences observed between the study and MAFs reported in the 
literature (Supplementary table 1).
Association of treatment failure with clinical and genetic factors in 
univariate and multivariable analysis
All patients: In univariate analysis, factors associated with failure of treatment were age 
(Odds ratio (OR) 0.58, 95% Confidence Interval (CI) 0.39–0.97, p = 0.039), use of adjuvant 
pain medication started on T0 or later (OR 3.04, 95% CI 1.76–5.24, p = 0.000), use of 
corticosteroids started on T0 or later (OR 1.95, 95% CI 1.15–3.29, p = 0.012), pain at rest 
(category severe pain OR 3.13, 95% CI 1.29–7.56, p = 0.011) and worst pain at T0 (category 
severe pain OR 3.21, 95% CI 1.19–8.69, p = 0.022), the MEDD at T0 (Q3: OR 2.27, 95% CI 
1.04–4.92, p = 0.038 and Q4: OR 3.10, 95% CI 1.45–6.63, p = 0.004) and the rs12948783 
SNP in RHBDF2 (OR 0.55, 95% CI 0.32–0.96, p = 0.035). Of these, the use of adjuvant 
pain medication (OR 3.49, p = 0.000), severe pain at rest (OR 2.67, p = 0.048) and the 
rs12948783 SNP in RHBDF2 (OR 0.37, p 0.056) were (possibly) independent as shown 
in multivariable analysis (tables 1-3). When the analysis was corrected for opioid dose, 
results were unchanged.
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Table 3. Results of univariate and multivariable analyses for all patients and per type of opioid 
Univariate analysis Multivariable analysis
Odds 
ratio
95% Confidence 
Interval
P Odds 
ratio
95% Confidence 
Interval
P
All
- Age
- Adjuvant pain medication 
≥ T0
- Corticosteroids ≥ T0
- Pain at rest 
Mild pain
Moderate pain
Severe pain
- Worst pain 
Mild pain
Moderate pain
Severe pain 
- Dose at T0
Q1
Q2
Q3
Q4
- rs12948783 (RHBDF2)
A carrier
0.58
3.04
1.95
1
1.1
3.13
1
1.28
3.21
1
1.91
2.27
3.10
0.55
0.39 – 0.97
1.76 – 5.24
1.15 – 3.29
0.44 – 2.78  
1.29 -  7.56
0.39 – 4.14
1.19 – 8.69
0.91 – 4.02 
1.04 – 4.92
1.45 – 6.63
0.32 - 0.96
0.039
0.000
0.012
0.840
0.011
0.686
0.022
0.086
0.038
0.004
0.035
3.49
1
1.25
2.67
0.37
1.87 – 9.29
0.47 – 3.34
1.01 – 7.04
0.14 – 1.03
0.000
0.656
0.048
0.056
Fentanyl
- Age
- Adjuvant pain medication 
≥ T0
- Corticosteroids ≥ T0
- Pain at rest 
Mild pain
Moderate pain
Severe pain
- Worst pain 
Mild pain
Moderate pain
Severe pain 
- Dose at T0
Q1
Q2
Q3
Q4
- rs1799971 OPRM1 
118G carrier
0.98
2.45
2.88
1
0.52
5.72
1
3.14
7.67
1
1.87
3.41
2.90
0.44
0.95 - 1.00
1.20 - 5.00
1.42 - 5.87
0.10 – 2.55
1.61 - 20.37
0.36 - 27.64
0.98 - 59.84
0.59 - 6.02
1.16 - 10.09
0.91 - 9.29
0.19 - 1.06
0.071 
0.013 
0.004
0.42
0.007   
0.30
0.052      
0.289
0.026
0.072
0.066
0.95
2.82
1
0.53
5.68
0.91 - 1.01
0.93 - 8.54
0.10 - 2.74
1.52 - 21.28
0.081
0.067
0.448
0.010
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Table 3. Continued
Univariate analysis Multivariable analysis
Odds 
ratio
95% Confidence 
Interval
P Odds 
ratio
95% Confidence 
Interval
P
Morphine
- Age
- Adjuvant pain medication 
≥ T0 
- Corticosteroids ≥ T0
- Dose at T0 
Q1
Q2
Q3
0.97
2.50
1.94
1
1.41
3.33
0.94 - 1.00
1.23 - 5.13
0.98 - 3.86
-
0.63 – 3.14
1.36 - 8.13
0.081 
0.012
0.058
0.40
0.008 
0.96
2.51
0.93 - 0.99
1.22 - 5.19
0.047
0.013
Oxycodone
- Adjuvant pain medication 
≥ T0
- rs12948783 (RHBDF2)
A carrier 
- rs7016778 (OPRK1)
T carrier 
6.22
0.23
0.30
1.69 - 22.88
0.06 - .88
0.09 - 1.00
0.006
0.032
0.050
11.18
0.19
0.20
2.21 - 56.40
0.03 - 1.12
0.04 - 1.09
0.003
0.066
0.063
≥ T
0
: started on T0 or during hospitalization, Q1 first quantile, Q2 second quantile, Q3 third 
quantile, Q4 fourth quantile 
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Fentanyl: In univariate analysis, factors associated with failure of fentanyl treatment 
were age (Odds ratio (OR) 0.98, 95% Confidence Interval (CI) 0.95–1.00, p = 0.071), use 
of adjuvant pain medication started on T0 or later (OR 2.45, 95% CI 1.20–5.00, p = 0.013), 
use of corticosteroids started on T0 or later (OR 2.88, 95% CI 1.42–5.87, p = 0.004), pain 
at rest (category severe pain OR 5.72, 95% CI 1.61–20.37, p = 0.007) and worst pain at T0 
(category severe pain OR 7.67, 95% CI 0.98–59.84, p = 0.052), the dose of fentanyl at T0 
(Q3: OR 3.41, 95% CI 1.16–10.09, p = 0.026 and Q4: OR 2.90, 95% CI 0.91–9.29, p = 0.072) 
and the rs1799971 SNP in OPRM1 (OR 0.44, 95% CI 0.19–1.06, p = 0.066). Of these, age (OR 
0.95, p = 0.081), the use of adjuvant pain medication (OR 1.83, p = 0.067), and severe pain 
at rest (OR 5.68, p = 0.010) were independent as shown in multivariable analysis (tables 
1-3). When the analysis was corrected for opioid dose the use of adjuvant pain medication 
was no longer significant (p = 0.106).
Morphine: For morphine, age (OR 0.97, 95% CI 0.94–1.00, p = 0.081), use of adjuvant 
pain medication started on T0 or later (OR 2.50, 95% CI 1.23–5.13, p = 0.012), use of 
corticosteroids started on T0 or later (OR 1.94, 95% CI 0.98–3.86, p = 0.058) and the dose 
of morphine at T0 (Q3 OR 3.33, 95% CI 1.36–8.13, p = 0.008) were found to be correlated 
with treatment failure in univariate analysis. None of the genetic variants correlated with 
failure of treatment (all: p > 0.10). In multivariable analysis use of adjuvant pain medication 
(OR 2.51, p < 0.013) and age (OR 0.96, p = 0.047) were found to correlate with treatment 
failure (tables 1-3). As for fentanyl, when the analysis was corrected for opioid dose, the 
use of adjuvant pain medication was no longer significant (p = 0.10).
Oxycodone: For oxycodone, use of adjuvant pain medication started on T0 or later (OR 
6.22, 95% CI 1.69–22.88, p = 0.006) and the SNPs rs12948783 (RHBDF2) (OR 0.23, 95% CI 
0.06–0.88, p = 0.032) and rs7016778 (OPRK1) (OR 0.30, 95% CI 0.09–1.00, p = 0.050) were 
identified in univariate analysis. In multivariable analysis, all three variables remained in 
the model, without and with correction for opioid dose on T0. (adjuvant pain medication 
OR 11.18, p = 0.003); rs12948783 in RHBDF2: OR 0.19 p = 0.066; rs7016778 in OPRK1: OR 
0.20, p = 0.063) (tables 1-3).
Hydromorphone: The number of patients in the hydromorphone group was considered 
too small for further analyses and to draw conclusions. 
Discussion
In this cohort of cancer patients treated with opioids, we found that in 20–34% treatment 
with fentanyl, morphine, oxycodone or hydromorphone failed because of insufficient 
pain control and/or dose limiting side effects. This is in line with previously reported data 
(1, 2, 26, 27). Clinical factors associated with treatment failure were the use of adjuvant 
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pain medication started after T
0
 and severity of pain at rest at T0. In the morphine 
and fentanyl cohorts, younger age was also associated with a worse outcome. For the 
selected SNPs, we identified rs12948783 (RHBDF2) and rs7016778 (OPRK1) as factors 
to be explored further in a future study. Previous studies assessing clinical risk factors 
for the need of opioid rotation have yielded variable results. In a large and prospective 
study, 118/345 (34.2%) patients underwent opioid rotation and no association between 
the need for rotation and pain type, use of adjuvant drugs or opioid doses was found (28). 
In another, retrospective, analysis, 103/273 patients (37.5%) rotated from their first line 
opioid. Although no correlation with age, type of pain or co-analgesics was found, the use 
of corticosteroids was associated with a significantly lower rate of opioid rotation (29). 
In our study, the use of corticosteroids was correlated with higher rates of failure, but 
only in the univariate analyses. A possible explanation is that in our cohort of patients, 
corticosteroids were given to patients with severe complex pain. It is also possible 
that corticosteroids may alter pharmacokinetics (e.g. by induction of CYP3A4) and 
pharmacodynamics of opioids. The association with the use of adjuvant pain medication 
is complex. Adjuvant drugs are preferentially used when a neuropathic mechanism may 
contribute to the clinical presentation. Neuropathic pain is more difficult to treat, as 
was shown in a validation study of the Edmonton Classification System for Cancer Pain. 
In that study, neuropathic pain and initial severity of pain were found to be significant 
predictors of pain complexity and positively correlated with the number of days needed 
to achieve stable pain control, the use of more adjuvants and higher doses of opioids (30). 
In another study in cancer patients using morphine, neuropathic pain was associated with 
a higher opioid escalation index (31). In our study, all patients had nociceptive pain but 
patients with a neuropathic component, were eligible. Adjuvant drugs were prescribed 
in case of a suspected neuropathic pain component, which were usually more complex 
pain syndromes. Further studies should assess neuropathic pain using validated tools. The 
correlation with age has been observed before. Ericson et al. reported a decrease in risk of 
treatment failure of 3% per 10-year increase in age. Above the age of 65 the risk decreased 
even 13% per 10-year increase (32). In the present analysis, the correlation between age 
and failure to morphine and fentanyl remained unchanged when the multivariable analysis 
was corrected for opioid dose at T0 and therefore the association cannot be explained 
by lower treatment doses in elderly patients. We can speculate that differences in opioid 
metabolism play a role or even that elderly patients and/or their doctors are less likely to 
report insufficient pain control or severe side effects because they are less demanding 
and/or more often fear dose escalation. Finally, the association with pain intensity at rest 
was not unexpected and was reported before (30).
The genetic analysis was also set-up as an exploratory analysis in order to identify candidate 
SNPs associated with treatment failure of (specific) opioids. While the frequencies of the 
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studied SNPs followed widely reported prevalence rates, none of the selected genetic 
variants were found to be significantly correlated with failure of treatment in the entire 
cohort and the fentanyl, morphine and oxycodone cohorts in the multivariable analysis. 
We did however find an association between the variant upstream of the RHBDF2 gene 
(rs12948783) and treatment outcome (p<0.10). In a previous genome wide association 
study (GWAS), this SNP was found to be significantly associated with decreased pain relief 
from opioids (33). As this gene is coding for inactive rhomboid protease, an enzyme that 
has been associated with cancer growth (34, 35), the found hit could be due to cancer 
demographics of the analyzed cohort, which were not specified in the GWAS study. In 
our cohort we observed a trend in the opposite direction, i.e. a lower rate of treatment 
failure. The distribution of tumor types might have been different which, combined with 
low number of patients, may explain these seemingly contradictory findings. Although 
the genetic variation (rs1672717) in the HTR3B gene, coding for the serotonin receptor 
subtype 3B, was previously associated with opioid induced nausea and vomiting in more 
than 1,500 Caucasian cancer patients (17), we did not find an association with opioid 
failure. Opioid failure is a composite endpoint and although a substantial part of patients 
failing treatment had dose limiting adverse events, the proportion of patients with severe 
nausea and vomiting as the main reason for treatment failure was probably too low to 
detect an association.
Interestingly, we found no correlation between the frequently investigated OPRM1 SNP 
(rs1799971) and opioid failure. A meta-analysis has illustrated the relevance of this SNP 
for opioid requirement in postoperative patients, especially within Asians treated with 
morphine for visceral pain (36), but the results have been conflicting for opioid response 
in cancer induced pain (14, 17, 37-43). Although genetic variation in the KCNJ6 gene has 
been previously associated with increased opioid requirement in postoperative pain (44) 
and a tendency toward less opioid effectiveness in chronic pain (45), this variant does not 
seem to predict opioid failure in our cohort. The minor allele of OPRK1 rs7016778 SNP has 
been previously associated with an increased experimental pain threshold (46). This could 
be caused by increased expression of the kappa receptor and as a consequence a higher 
affinity for endogenous opioids. Since oxycodone may exert (part of) its analgesic effect 
primarily via the kappa receptor (47), it is expected that OPRK1 genetic variants could 
alter the response and thus the need to switch to a non-kappa-binding opioid. While the 
relevance of the kappa receptor above the mu-opioid receptor for oxycodone has been 
discussed (48), in our cohort carriers of the minor allele had a (non-statistically significant) 
lower risk of treatment failure with oxycodone, which is in line with the decreased pain 
sensitivity reported in the experimental pain setting. Lastly, none of the SNPs related to 
metabolism of specific opioids (CYP3A4, CYP2D6, OCT1, UGT2B7 and ABCC3) correlated 
with failure of treatment in our analysis. This might be due to our limited sample size. 
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Furthermore, up till now little is known about the effect of changes in pharmacokinetics on 
pharmacodynamics.
Although we assembled longitudinal data in a large group of cancer patients and studied 
a clinically relevant endpoint we must also acknowledge some limitations. Per treatment 
group numbers were small and the included population was heterogeneous in terms of 
treatment phase with opioids and opioid dose at T
0
. Furthermore we compared patients in 
whom treatment failed with patients in whom treatment did not fail. Although we strictly 
defined failure of treatment, we categorised all other patients as not failing treatment 
although some may not have been successfully treated. Also, we studied failure as a 
composite endpoint although analgesia and (central) side effects may be independent 
treatment outcomes (38). Sample size did not allow us to create subgroups according to the 
reason(s) of failure. 
In conclusion, we have identified that the use of adjuvant pain medication, pain 
intensity at rest and age were associated with failure of treatment with fentanyl, 
morphine, oxycodone and hydromorphone in this exploratory study. Furthermore, a 
trend to a negative correlation with treatment failure was seen for the single nucleotide 
polymorphisms rs12948783 (RHBDF2) in all patients and the oxycodone cohort and for 
rs7016778 (OPRK1) in the oxycodone cohort. As these factors are not opioid specific, they 
cannot be used to guide treatment and the choice for a specific type of opioid. The variant 
rs7016778 (OPRK1) warrants further research with this respect. Ideally, future studies 
should include large and homogeneous patient populations and protocolise treatments 
strictly. However, such a trial will be difficult – if not impossible – to perform in a palliative 
clinical care setting.
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Supplemental material 
Supplementary Table 1. Genotype frequencies and HW-equilibrium
SNP n MAF study (%) MAF Literature (%) HW (p-value)
CYP3A4 rs2242480 (*1G)
*1/*1
*1/*1G
*1G/*1G
175
41
6
12 7 0.07
CYP3A4 rs35599367 (*22)
*1/*1
*1/*22
*22/*22
196
25
0
6 5 0.37
CYP2D6 rs35742686 (*3)
*1/*1
*1/*3
*3/*3
71
7
0
4 2 0.68
CYP2D6 rs3892097 (*4)
*1/*1
*1/*4
*4/*4
48
23
5
21 28 0.34
CYP2D6 deletion (*5)
Negative
Positive 
76
3
2 5 0.86
CYP2D6 rs5030655 (*6)
*1/*1
*1/*6
*6/*6
76
3
0
2 1 0.86
CYP2D6 rs28371725 (*41)
*1/*1
*1/*41
*41/*41
65
13
1
9 9 0.71
CYP2D6 XN
Negative
Positive
76
3
2 3 0.86
UGT2B7 rs7438135
GG
GA
AA
49
77
33
45 50 0.79
OCT1 rs72552763 (*2)
*1/*1
*1/*2
*2/*2
247
86
10
21 15 0.45
OCT1 rs12208357 (*3)
*1/*1
*1/*3
*3/*3
298
43
3
8 10 0.31
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SNP n MAF study (%) MAF Literature (%) HW (p-value)
OCT1 rs34130495 (*4)
*1/*1
*1/*4
*4/*4
319
26
0
4 2 0.47
OCT1 rs34059508 (*5)
*1/*1
*1/*5
*5/*5
336
9
0
1 1 0.81
ABCC3 rs4793665
CC
CT
TT
38
75
44
52 49 0.59
COMT rs4680
GG
GA
AA
85
160
95
51 48 0.28
COMT rs4818
CC
CG
GG
141
144
56
37 42 0.07
COMT rs4633
CC
CT
TT
83
161
97
51 48 0.35
OPRM1 rs1799971
AA
AG
GG
269
68
5
11 16 0.77
KCNJ6 rs2070995
AA
AG
GG
9
112
217
79 80 0.22
RHBDF2 rs12948783
CC
CT
TT
246
89
8
15 15 0.99
HTR3B rs1672717
CC
CT
TT
57
152
133
60 58 0.23
OPRK1 rs7016778
AA
AT
TT
255
81
4
13 12 0.38
OPRK1 rs7824175
CC
CG
GG
274
64
3
10 10 0.73
Supplementary Table 1. Continued
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Chapter 7
    Summary, discussion and 
future	perspectives
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Summary and discussion
The prevalence of pain is high in patients with cancer during all stages of their disease. 
The highest rates, more than 70%, are seen in patients with advanced stages of cancer. 
Pain is also one of the most feared symptoms by patients, as well as their families. In 
unselected cohorts, pain is adequately controlled in only 50% of cancer patients (1). 
We therefore face a major challenge when it comes to improving the treatment of 
cancer-related pain. In this process, many steps are important, starting with identifying 
patients with pain and overcoming barriers hindering adequate management of cancer 
pain, such as knowledge deficits, inadequate pain assessment and misconceptions 
regarding pain (2). We also face many challenges when it comes to pharmacologic 
interventions for cancer-related pain. The optimal sequence and combinations of non-
opioid, opioid, and adjuvant analgesics are largely unknown due to the current lack of high 
quality clinical trials. Although opioids are the backbone in the treatment of moderate to 
severe pain, the causes for the variable treatment outcomes are incompletely understood 
and from the variety of available opioids we try to find the best type and dose for an 
individual patient by trial and error. In order to improve and personalize treatment we 
need to expand our knowledge. The studies described in this thesis, were performed 
with the intention to expand our knowledge of the outcomes of treatment with various 
opioids and to find clinical, pharmacokinetic and (pharmaco-) genetic factors associated 
with variations in treatment outcomes. Ideally, these factors can then be used to guide 
treatment.
The study described in chapter 2 can be seen as the basis for the other studies in this 
thesis. We performed a retrospective analysis in a cohort of 157 cancer patients who died 
during a hospitalisation on our specialised unit for acute palliative care. In this cohort, 
68 patients had an indication for continuous palliative sedation prior to death. From a 
previous analysis (3), we knew that the most common indication for palliative sedation 
in this cohort of patients was terminal restlessness (60%) and that ultimately sedated 
patients more often suffered from delirium as compared to non-sedated patients. 
Moreover, we knew that in both groups of patients, pain was the most prevalent 
symptom on admission and that it’s prevalence remained high during admission (3). As a 
delirium is often drug induced and opioids are amongst the most frequently implicated 
drugs, we studied differences in pain medication and other medication with potential 
cognitive side effects between ultimately sedated and non-sedated patients. We found 
some striking differences between the use of pain medication between the two groups. 
Patients in the ultimately sedated group, were already treated with higher doses of 
opioids on admission (Median Equianalgesic daily dose (MEDD) 270 mg versus 120 mg) 
and the differences between the MEDD increased further in the final 72h before death. 
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Furthermore, ultimately sedated patients were switched to other opioids more often (44 
versus 22%) and were more frequently treated with adjuvant analgesics. 
These data support the assumptions that in a subset of patients, pain is more complex 
and difficult to treat, that a disturbed dose-effect relationship for opioids may exist in 
these patients and that intensive treatment of pain may have severe consequences for 
these patients. These findings raise some important new questions. 
Although it is known that in about 30% of patients, treatment with a first opioid is 
unsuccessful due to the occurrence of dose-limiting side effects and/or insufficient 
pain control (4, 5), and that opioid rotation can be successful in these cases, we do not 
know in how many patients treatment with various opioids consecutively is ultimately 
unsuccessful. More importantly, we do not know which patient will have unwanted 
outcomes of treatment and what distinguishes them from patients who can be treated 
successfully. And why treatment with a specific opioid is successful in some patients 
but unsuccessful in others. Are there differences in clinical effects between the various 
opioids? What are the main causes for the large differences in required doses? And can we 
find factors that can be used to guide opioid treatment in individual patients? Or can we 
identify a subgroup of patients in whom treatment with all opioids is likely to fail? With 
the aim of answering some of these questions, the other studies described in this thesis, 
were performed. 
To start with, we went back to the basics in chapter 3 where we tried to answer the question 
whether the incidence of specific side effects differs among frequently used types of 
opioids. We conducted a systematic review, including only prospective studies reporting 
adverse events (AEs) in patients treated with the opioids morphine, oxycodone, fentanyl, 
methadone or hydromorphone for cancer-related pain. Furthermore, we selected studies 
including patients naive to treatment with step III opioids. We included 25 studies, 
reporting on 31 treatment cohorts and made an overview of reported rates of AEs per 
type of opioid. In general, reported rates of AEs were high but we were confronted with 
very broad ranges in reported rates of all AEs. With the available data, it was not possible 
to create an overview of the true incidence of AEs per type of opioid and to compare these 
rates for the various opioids. 
This was due to large heterogeneity between the studies, especially regarding the 
assessment and reporting of AEs. Furthermore, there is a lack of studies in opioid naive 
patients and – surprisingly – little attention is given to AEs when performing clinical trials. 
In many studies, there was no systematic assessment of AEs and even when AEs were 
reported as outcome parameter, most studies reported only a fraction of AEs frequently 
encountered in daily clinical practice. The most frequently reported AEs were nausea, 
vomiting, constipation, drowsiness and dry mouth. However, other AEs may also be 
prevalent and have a high(er) impact on quality of life. For example, itching, myoclonus, 
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hallucinations and confusion are AEs quite common in clinical practice (6, 7) but were 
only rarely assessed and reported. And although dry mouth seems to be one of the most 
frequently occurring AEs with a high impact on quality of life (7) , only 8 out of 25 studies 
reported this AE. 
Next, we performed two pharmacokinetic studies, described in chapters 4 and 5. In 
chapter 4 we published the results from a population pharmacokinetic study in a cohort 
of patients treated with fentanyl administered subcutaneously by continuous and bolus 
infusion and/or transdermally. By inclusion of 942 samples from 52 cancer patients, a 
non-linear mixed effects model (NONMEM) was built. A one-compartment model with 
first-order elimination and separate first-order absorption processes for each route best 
described the data. For 14 patients clinical and pharmacokinetic data were available 
around rotations from subcutaneous to transdermal fentanyl using a 12-hour rotation 
scheme, and by using the final model we also simulated a 6-hour rotation scheme. 
Several findings from this study may be relevant for clinical practice and warrant 
further studies. Firstly, we report moderate to high variability in PK parameters and 
plasma concentrations for transdermal as well as for subcutaneous fentanyl. Assuming 
a correlation between plasma concentrations of fentanyl and clinical effects, these data 
emphasize the need for individual dose titration. Secondly, when treating patients with 
transdermal fentanyl it is crucial to consider that fluctuations in plasma concentrations 
occur during the recommended treatment period of 72 hours per patch, as absorption 
seems to be closer to a first-order (i.e. concentration dependent) than to a zero-order (i.e. 
concentration independent) process. This may lead to changes in pain control and/or the 
occurrence of side effects during the 72 h application period. Thirdly, we estimated a rather 
low absorption rate constant for subcutaneous fentanyl. If this finding can be confirmed, 
we may conclude that continuous subcutaneous fentanyl may not be as suitable for fast 
titration as previously assumed. It may be, that for fast titration, intravenous fentanyl 
should be preferred, while – for example – in patients in an outpatient setting without 
an indication for fast titration, continuous infusion of subcutaneous fentanyl may be 
preferred in case of a contra-indication for patches. Lastly, we observed a rise in plasma 
concentrations of fentanyl when rotating the route of administration from subcutaneous 
to transdermal, and this led to toxicity in 12 out of 14 patients with pharmacokinetic and 
clinical data available around this rotation. As the simulated 6-hour scheme produced 
similar results (i.e. a similar rise in plasma concentrations of fentanyl), we suggest that 
overlap in routes should not be used, while earlier performed studies with rotations from 
intravenous to transdermal fentanyl recommended a 6 hour overlap of routes (8, 9). 
In chapter 5, we report results from a population pharmacokinetic study in a cohort of 
patients treated with continuous and bolus subcutaneously and/or orally (slow-release 
and/or immediate release) administered morphine. Data were again analysed by using 
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NONMEM. Plasma concentrations of morphine and metabolites (morphine-3- and 
6-glucuronide; M3G and M6G) were best described by a one-compartment model with 
the metabolites formed via first-order elimination as well as first pass metabolism. We 
were able to estimate bio-availability of oral morphine to 37.2%, thereby confirming 
the recommended dose conversion ratio of 1:3 for rotations from subcutaneous to 
oral morphine. Furthermore, we report AUC ratios (M3G:morphine; M6G: morphine 
and M3G:M6G) for oral compared to subcutaneous administration. As expected, the 
subcutaneous route of administration, which avoids first-pass metabolism, resulted 
in a lower ratio of M3G:morphine and M6G: morphine. The ratio M3G:M6G remained 
constant. Substantial intra- and inter-individual variability in PK parameters was found. 
We therefore studied the effect of several clinical and genetic covariates on the clearances 
of morphine and the metabolites. We also explored whether the variability in morphine 
clearance is related to treatment outcome. Age, gender, renal function and genetic variants 
in genes coding for the metabolizing enzyme UGT2B7 (rs7438135) and the membrane 
drug transporters OCT1 (rs72552763, rs12208357, rs34130495, rs34059508) and ABCC3 
(rs4793665) were not found to be significant predictors of the clearance of morphine, and/
or the clearances of M3G and M6G. The clearance of M3G and M6G however was found to 
be a function of body weight and renal function. The clearance of morphine did not differ 
significantly between patients failing treatment with morphine and patients not failing 
treatment. The effects of the large variations in concentrations of morphine, M3G and 
M6G on clinical outcomes should be further explored, as this may have consequences for 
treatment. 
Limitations from both studies mainly arise from the fact that both studies were performed 
in a real life clinical setting and by following clinical practice. Therefore, most patients 
were being titrated with fentanyl/morphine during study participation and the frequent 
dose changes and use of rescue medication made the analyses of PK data more complex. 
Also, in many patients plasma samples were taken after semi-simultaneous administration 
of opioids by different routes. For example, the majority of patients treated with 
subcutaneous fentanyl was treated with a patch before, which, due to the long terminal 
half-life made it difficult to estimate the contribution of each route of administration to 
the measured plasma level. 
In chapter 6, we report an analysis that was performed with the aim to find clinical and 
(pharmaco-) genetic factors associated with treatment outcome. Here, we selected several 
factors from the literature and tested these for a correlation with treatment failure in the 
entire cohort consisting of 356 patients and after categorising each patient in cohorts per 
type of opioid patients were treated with. Treatment failure was defined as a rotation to 
another type of opioid, treatment with intrathecal opioids, both because of insufficient 
pain control and/or side effects, or the use of palliative sedation because of refractory 
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symptoms associated with opioid treatment in the dying phase. In all other patients the 
outcome of treatment was considered as non-failure. As this was an explorative analysis, 
factors with a p-value of < 0.10 in univariate analysis were entered into multivariable 
analysis and data were not corrected for multiple testing. In multivariable analysis, younger 
age, the use of adjuvant pain medication, and pain intensity at rest were associated with 
failure of treatment with fentanyl, morphine and oxycodone. Furthermore, the single 
nucleotide polymorphisms (SNPs) rs12948783 (RHBDF2) and in the oxycodone cohort 
rs7016778 (OPRK1) showed a trend to a negative correlation with treatment failure. The 
role of these two genetic variants should be further explored, noting that the RHDBF2 SNP 
was identified in a genome wide association study (GWAS) that reported patients carrying 
the studied variant had decreased pain relief from opioids while in our analysis we found 
a trend towards a lower rate of treatment failure. The associations between the clinical 
factors and treatment failure were not unexpected, although the relationship between 
age and treatment outcome is interesting. None of these factors, except maybe the 
OPRK1 SNP, seem to be opioid specific and can therefore not be used to guide treatment 
with individual opioids.
Importantly, none of the SNPs related to metabolism of specific opioids (CYP3A4, CYP2D6, 
OCT1, UGT2B7 and ABCC3) correlated with failure of treatment in our analysis, which 
supports the data reported in chapter 5.
General conclusions and future perspectives 
Despite all efforts described above, we are still far away from truly individualising opioid 
treatment based on prognostic and predictive factors. This seems to be due, at least 
partly, to our incomplete understanding of the mechanisms of action involved in opioid 
treatment. These actions can be defined at the level of the receptor, the cell, and in the 
modulation of circuitry within the nervous system. Although much progress has been 
made in the past decades, the challenge to integrate the various areas of investigation 
remains (12). Once we have unravelled all factors that may be of influence on treatment 
outcomes, we can study the effects of variations in these factors using a more structured 
approach. We should learn from the abundance of cancer research, in which the biology of 
cancer is being unravelled step by step, leading to highly targeted treatment approaches 
and combinations. 
The lack of well performed studies with opioids limits the ability to draw firm conclusions 
on the role of clinical factors for specific opioids. There is a need for investigator driven, 
high quality clinical trials with opioids. In order to make this possible, such studies should 
be subsidised by independent parties and we should renounce the notion that performing 
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research in a palliative care setting is either unethical or too difficult to perform. The 
inclusion of participants in palliative care studies has no unique risk factors, although 
there is more often an accumulation of factors hampering inclusion. Preparing for these 
by use of a specifically created checklist might prevent or at least reduce problems with 
inclusion (13).
Furthermore, international consensus should be sought on the use of validated assessment 
tools for pain and adverse events specific to palliative care, as has been suggested in a 
recent Cochrane review as well (14). 
Regarding the pharmacokinetic studies, one of the difficulties is the fact that the opioid 
receptors are mainly located in the central nervous system. As the effects of opioids are 
dependent on the concentrations available at the receptor sites, we should possibly first 
explore the correlation between drug concentrations in cerebrospinal fluid (CSF) versus 
plasma. Although some efforts have been made in this area (15-18), our knowledge for 
the various opioids is still insufficient. To minimise patient burden, such studies could 
be performed in healthy volunteers or we should consider collecting samples from 
patients with another indication for a lumbar puncture. Furthermore, when performing 
pharmacokinetic studies, the challenge should be to design studies with a limited number 
of well-timed samples, while limiting disturbing factors (such as dose changes or extra 
doses of medication). The challenge will be to disrupt clinical practice as little as possible 
in order to minimize the burden of study participation for patients, while optimizing 
circumstances for performing studies. Future clinical studies could, for instance, focus 
on exploring the relationship between plasma and/or CSF concentrations of opioids and 
clinical outcomes, on finding ways to create more stable plasma concentrations during 
treatment with transdermal fentanyl and on optimising opioid rotation schemes for 
changes in route of administration and types of opioids. 
To study the effects of genetic variations in more detail, we should ideally expand our 
knowledge on factors influencing the outcomes of opioid treatment first, so that we 
can study (pharmaco-) genetic variations more focused on specific pathways. As the 
outcome of treatment seems to be the result of a complex interplay of clinical, genetic 
and pharmacokinetic factors, it seems unlikely that one SNP will significantly influence 
treatment outcome. We may therefore need to focus on finding ‘gene panels’ by including 
combinations of SNPs involved in any step of the involved pathways. As long as our 
knowledge on these pathways is insufficient, GWAS might help to identify relevant SNPs 
and pathways. Such GWAS should ideally be performed in large, homogeneous patient 
populations and require objective criteria for defining treatment failure. Such studies will 
therefore be difficult to perform. 
Lastly, as research on opioids is not frequently performed and is too specific for cancer 
journals, we experienced some difficulties in finding appropriate journals for the 
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publication of our results. In our opinion this is partly due to the fact that palliative care 
belongs to no one while it should belong to everyone. As the prevalence of pain is high in 
cancer patients, all physicians involved in treatment of patients with cancer, should also 
have knowledge on treatment of cancer-related pain. Hopefully, the current attention 
for palliative care in the political domain but also in the public domain, will yield more 
attention for (clinical) research performed in this area and lead to better possibilities for 
publications that reach a wide medical audience.
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Samenvatting, discussie en aanbevelingen
Pijn komt veel voor bij patiënten met kanker, gedurende alle stadia van de ziekte. Vooral 
bij patiënten met gevorderde stadia van kanker komt pijn veel voor, bij meer dan 70%. 
Daarnaast is pijn één van de symptomen die – zowel door patiënten als door hun naasten 
– het meest gevreesd worden. In niet geselecteerde groepen van patiënten met kanker, 
bleek bij slechts 50% van hen de pijn voldoende gestild te zijn (1). Het verbeteren van de 
behandeling van kanker-gerelateerde pijn is daarom een enorme uitdaging. Hierbij zijn 
vele stappen belangrijk, te beginnen met het vinden en herkennen van patiënten met pijn 
en het overwinnen van barrières die adequate behandeling van pijn bemoeilijken; zoals 
gebrek aan kennis, inadequate beoordeling van pijn en misvattingen aangaande pijn (2). 
Ook op het gebied van medicamenteuze behandeling van kanker-gerelateerde pijn, zijn 
er vele uitdagingen. De optimale volgorde en combinaties van niet-opioïde-, opioïde- 
en aanvullende pijnmedicatie zijn grotendeels onbekend als gevolg van een gebrek aan 
goed opzette klinische studies. Hoewel opioïden de basis vormen van de behandeling van 
matig tot ernstige pijn, is onvoldoende bekend wat de oorzaken zijn voor de wisselende 
uitkomsten van behandeling. We proberen voor een individuele patiënt het beste middel 
in de optimale dosering te vinden door ‘trial and error’ – oftewel door wanneer dat nodig 
is verschillende middelen en doseringen uit te proberen. Om de behandeling te kunnen 
verbeteren en meer op de individuele patiënt af te stemmen, is meer kennis nodig. De 
onderzoeken die beschreven staan in dit proefschrift, zijn uitgevoerd met als doel onze 
kennis omtrent uitkomsten van behandeling met opioïden te verbeteren, en om klinische, 
farmacokinetische en (farmaco-)genetische factoren te vinden die geassocieerd zijn met 
variaties in uitkomsten van behandeling. Idealiter, kunnen deze factoren vervolgens 
gebruikt worden om te helpen bij het maken van keuzes in de behandeling.
De studie die beschreven staat in hoofdstuk 2, kan gezien worden als een basis voor de 
rest van de onderzoeken in dit proefschrift. We voerden een retrospectieve analyse uit, 
in een groep van 157 patiënten met kanker die overleden tijdens een ziekenhuisopname 
op onze gespecialiseerde unit voor palliatieve zorg. Binnen deze groep, bestond er bij 
68 patiënten een indicatie voor continue palliatieve sedatie tot aan het overlijden. Uit 
een eerdere analyse van ditzelfde cohort (3), wisten we dat terminale onrust de meest 
voorkomende indicatie was voor palliatieve sedatie (60%) en dat patiënten die uiteindelijk 
gesedeerd moesten worden vaker een delier hadden dan patiënten zonder indicatie voor 
sedatie. Ook wisten we dat – in beide groepen – pijn het meest voorkomende symptoom 
was bij opname en dat de prevalentie van pijn hoog bleef gedurende de opname (3). Omdat 
een delier vaak veroorzaakt wordt door medicatie, waarbij opioïden een veel genoemde 
oorzaak zijn, onderzochten we verschillen in het gebruik van pijnmedicatie en andere 
medicatie die cognitieve bijwerkingen kan veroorzaken, tussen uiteindelijk gesedeerde 
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en niet gesedeerde patiënten. We vonden daarbij opmerkelijke verschillen in het gebruik 
van pijnmedicatie tussen de twee groepen. 
Patiënten in de uiteindelijk gesedeerde groep, werden al bij opname met hogere 
doseringen van opioïden behandeld (Mediane Equianalgetische dag dosering (MEDD) 270 
mg versus 120 mg), waarbij de verschillen in de MEDD verder opliepen in de laatste 72 
uur voor het overlijden. Ook vond bij de gesedeerde patiënten vaker een opioïd rotatie 
plaats (44 versus 22%) en werden deze patiënten vaker met aanvullende pijnmedicatie 
behandeld. 
Deze data geven steun aan de aannames dat bij een deel van de patiënten pijn meer 
complex en moeilijker behandelbaar is, dat er bij deze patiënten een verstoorde balans 
bestaat tussen de dosis en de effecten van opioïden en dat intensieve behandeling van 
pijn bij deze patiënten ernstige gevolgen kan hebben. De bevindingen roepen belangrijke, 
nieuwe vragen op.
Hoewel bekend is dat, bij ongeveer 30% van de patiënten, behandeling met een eerste 
opioïd niet succesvol is ten gevolge van het ontstaan van dosis-limiterende bijwerkingen 
en/of onvoldoende pijncontrole (4, 5), en dat een opioïd rotatie (verandering naar een 
ander soort opioïd) bij deze patiënten succesvol kan zijn, is niet bekend bij hoeveel 
patiënten behandeling met opeenvolgende, verschillende opioïden uiteindelijk niet 
succesvol is. Belangrijker is nog, dat ook niet bekend is bij welke patiënten dit zal 
gebeuren en wat hen onderscheid van patiënten die wel succesvol behandeld kunnen 
worden. En waarom behandeling met een specifiek opioïd bij de ene patiënt wel, en bij 
de andere patiënt niet succesvol is. En of er verschillen zijn in de klinische uitkomsten van 
de verschillende opioïden of wat de belangrijkste oorzaken zijn voor de grote verschillen 
in benodigde doseringen. En kunnen we factoren vinden die we kunnen gebruiken om 
sturing te geven aan behandeling met opioïden bij individuele patiënten? Of kunnen we 
die patiënten identificeren bij wie behandeling met alle opioïden waarschijnlijk zal falen? 
De andere onderzoeken, die beschreven staan in dit proefschrift, werden uitgevoerd met 
het doel een deel van deze vragen te beantwoorden.
In hoofdstuk 3, zijn we bij de basis begonnen doordat we hebben geprobeerd een antwoord 
te vinden op de vraag of er een verschil is in de incidentie van specifieke bijwerkingen 
tussen verschillende, veel gebruikte opioïden. We hebben daarom een systematische 
review uitgevoerd, waarin we alleen prospectieve studies includeerden die bijwerkingen 
rapporteerden van patiënten die voor kanker-gerelateerde pijn werden behandeld met 
morfine, oxycodon, fentanyl, methadon of hydromorfon. We selecteerden alleen studies 
waarin patiënten werden geïncludeerd die niet eerder met deze opioïden behandeld 
waren, omdat gewenning op kan treden en zodat patiënten die vanwege falen op een 
eerder opioïd roteerden, niet meegenomen werden. We konden 25 studies includeren, 
die rapporteerden over 31 behandel groepen, waarna we per type opioïd, een overzicht 
146
maakten van het gerapporteerde aantal bijwerkingen. Hoewel gemiddeld genomen bij 
grote aantallen patiënten bijwerkingen gerapporteerd werden, was de spreiding erg 
groot. Met de beschikbare gegevens lukte het niet om per type opioïd een overzicht te 
maken van de daadwerkelijke incidentie van bijwerkingen (het aantal nieuw ontstane 
symptomen/bijwerkingen na start van een opioïd) en om deze incidenties te vergelijken. 
Dit kwam door grote verschillen tussen de studies, vooral aangaande het beoordelen 
en rapporteren van bijwerkingen. Er is een tekort aan studies die zijn uitgevoerd bij 
niet eerder met opioïden behandelde patiënten en – tot onze verbazing – is er maar 
weinig aandacht voor bijwerkingen binnen klinische studies. In veel studies was geen 
systematische beoordeling van bijwerkingen gedaan, en wanneer wel bijwerkingen 
werden gerapporteerd, betrof het vaak slechts een fractie van de bijwerkingen die in de 
dagelijkse praktijk veel gezien worden. De meest gerapporteerde bijwerkingen waren 
misselijkheid, braken, obstipatie, sufheid en droge mond. Andere bijwerkingen komen 
echter ook veel voor en kunnen een grote(re) invloed hebben op de kwaliteit van leven. 
Zo komen bijvoorbeeld jeuk, myoclonieën, hallucinaties en verwardheid regelmatig voor 
(6, 7), maar werden deze bijwerkingen slechts zelden uitgevraagd en gerapporteerd. En 
hoewel droge mond één van de meest voorkomende bijwerkingen lijkt te zijn met een 
grote invloed op kwaliteit van leven (7), rapporteerden slechts 8 van de 25 studies deze 
bijwerking. 
Vervolgens hebben we twee farmacokinetiek (PK) studies uitgevoerd, die worden 
beschreven in hoofdstukken 4 en 5. In hoofdstuk 4 zijn resultaten gepubliceerd uit een 
populatie farmacokinetiek studie in een patiënten cohort dat behandeld werd met 
continue en bolus subcutaan (onderhuidse) en/of transdermaal (via de huid, pleister) 
toegediende fentanyl. Door inclusie van 942 samples verkregen van 52 patiënten met 
kanker, kon een non-linear mixed effects (NONMEM) model worden gebouwd. Dit is 
een wiskundig model dat om de data heen wordt gebouwd en waarin rekening wordt 
gehouden met een niet rechtlijnig verband tussen onderzochte variabelen en uitkomsten 
en met verschillende bekende maar ook onbekende factoren, die invloed kunnen 
hebben op de farmacokinetiek. Met een 1-compartiment model met 1e orde eliminatie 
(per tijdseenheid wordt een constante fractie van de nog aanwezige stof uitgescheiden 
of omgezet in een andere stof, een metaboliet) en aparte 1e orde absorptie (absorptie 
snelheid afhankelijk van concentratie) voor beide routes konden de data het beste worden 
beschreven. Bij 14 patiënten waren klinische en farmacokinetische gegevens beschikbaar 
rondom rotaties van subcutaan naar transdermaal fentanyl met een 12-uur durende 
overlap van de routes, en met het uiteindelijke model kon ook een schema met 6 uur 
overlap worden gesimuleerd. Meerdere bevindingen uit deze studie kunnen belangrijk 
zijn voor de dagelijkse praktijk en verdienen verder onderzoek. Ten eerste rapporteren we 
matige tot hoge variatie in PK parameters en plasma concentraties van fentanyl, zowel 
147
A
voor de transdermale als de subcutane route. Wanneer we aannemen dat er een verband 
is tussen de plasma concentratie van fentanyl en de klinische effecten, onderstrepen 
deze data dat de dosering altijd individueel getitreerd moet worden. Ten tweede is het 
belangrijk dat we ons realiseren dat plasma concentraties van fentanyl niet stabiel zijn 
gedurende de aanbevolen behandelduur van 72 uur per pleister. Dit komt doordat de 
absorptie via een 1e orde proces lijkt te verlopen (afhankelijk van concentratieverschil) 
in plaats van via een 0e orde proces (niet afhankelijk van concentratieverschil). De 
schommelingen in plasma concentraties kunnen leiden tot veranderingen in pijncontrole 
en bijwerkingen gedurende de 72 uur dat een fentanyl pleister geplakt blijft. Ten derde, 
is de door ons geschatte absorptieconstante voor subcutaan fentanyl vrij laag. Als deze 
bevinding kan worden bevestigd, kan dit betekenen dat continue subcutaan toegediende 
fentanyl minder geschikt is voor snelle titratie. Daarvoor moet dan misschien intraveneus 
fentanyl gebruikt worden, terwijl bijvoorbeeld bij poliklinische patiënten waarbij er geen 
reden is voor snelle titratie, continue subcutane infusie de voorkeur kan hebben wanneer 
behandeling met pleisters niet lukt of niet mogelijk is. Tenslotte, zagen we een stijging in 
plasma concentraties van fentanyl bij rotaties van subcutaan naar transdermaal fentanyl. 
Bij 12 van de 14 patiënten waarvan zowel PK als klinische gegevens beschikbaar waren, 
leidde dit tot (een toename van) bijwerkingen. Omdat het gesimuleerde schema met 6 
uur overlap eenzelfde stijging liet zien van de plasma concentratie, suggereren we dat 
het continueren van de subcutane infusie na aanbrengen van de pleister vermeden moet 
worden, terwijl eerdere studies rondom rotaties van intraveneus naar transdermaal 
fentanyl juist adviseerden om de intraveneuze toediening dan nog 6 uur te continueren 
(8, 9). 
In hoofdstuk 5, beschrijven we de resultaten van een populatie farmacokinetiek studie 
in een cohort van patiënten met kanker die werden behandeld met continue en bolus 
subcutaan en/of oraal (vertraagde of onmiddellijke afgifte) toegediende morfine. De 
data werden wederom geanalyseerd met NONMEM. Morfine en de metabolieten 
(morfine-3- en 6-glucuronide; M3G en M6G) konden het beste worden beschreven door 
een 1-compartiment model waarbij de vorming van de metabolieten plaats vond via 
1e orde eliminatie van morfine en waarin het effect van de eerste leverpassage (First 
pass effect) was meegenomen. De biologische beschikbaarheid van oraal morfine kon 
worden geschat op 37.2%, waarmee de aanbevolen verhouding in dosering van 1:3 bij 
omzetting van subcutaan naar oraal morfine kan worden bevestigd. Ook rapporteren 
we AUC (area under the curve) ratio’s (M3G:morfine, M6G:morfine en M3G:M6G) voor 
oraal vergeleken met subcutaan toegediende morfine. Zoals verwacht, zijn de ratios 
M3G:morfine en M6G:morfine lager na subcutane toediening doordat het effect van de 
eerste leverpassage vermeden wordt. De verhouding M3G:M6G blijft wel constant. We 
rapporteren behoorlijke variatie in PK parameters tussen verschillende patiënten maar 
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ook binnen dezelfde patiënten. Daarop hebben we het effect van verschillende factoren 
op de klaring van morfine en de metabolieten onderzocht en het verband tussen klaring 
van morfine en uitkomst van behandeling geëxploreerd. We vonden dat leeftijd, geslacht, 
nierfunktie en genetische variaties in genen die coderen voor het metaboliserende 
enzym UGT2B7 (rs7438135) en de membraneuze drug transporters OCT1 (rs72552763, 
rs12208357, rs34130495, rs34059508) en ABCC3 (rs4793665) geen significante voorspellers 
waren van de klaring van morfine. De klaring van de metabolieten bleek een funktie van 
lichaamsgewicht en nierfunktie te zijn. De klaring van morfine verschilde niet significant 
tussen patiënten bij wie de behandeling met morfine faalde en patiënten bij wie deze 
behandeling niet faalde. De invloed van de aanzienlijke variaties in concentraties van 
morfine, M3G en M6G op de uitkomsten van behandeling moeten verder onderzocht 
worden. 
Beperkingen van beide studies komen vooral voort uit het feit dat beide werd uitgevoerd 
door het volgen van de dagelijkse praktijk tijdens een ziekenhuisopname. Als gevolg 
daarvan, werden veel patiënten gedurende hun deelname aan de studie getitreerd met 
fentanyl/morfine waarbij frequente dosisaanpassingen en gebruik van extra (rescue) 
doseringen nodig waren. Dit maakte de analyse van de PK data ingewikkelder. Ook 
werden bij veel patiënten samples verkregen na semi-gelijktijdige toediening van 
opioïden via verschillende routes. Zo was de meerderheid van de patiënten die behandeld 
werden met subcutaan fentanyl daarvoor met fentanyl pleisters behandeld. Door de lange 
halfwaardetijd was het daardoor moeilijk om de bijdrage van iedere route aan de gemeten 
plasma concentratie te schatten. 
In hoofdstuk 6 beschrijven we een analyse die werd uitgevoerd met als doel om klinische 
en (farmaco-) genetische factoren te vinden die samenhangen met de uitkomsten van 
behandeling. 
We selecteerden daarvoor verschillende factoren vanuit de literatuur en testten 
vervolgens of deze verband hadden met falen van de behandeling in het gehele cohort 
van 353 patiënten en na het verdelen van de patiënten in behandelcohorten per type 
opioïd. Het falen van een behandeling was gedefinieerd als de noodzaak tot een 
rotatie naar een ander type opioïd of behandeling met intrathecale opioïden (via een 
ruggenprik) vanwege onvoldoende pijncontrole en/of dosis beperkende bijwerkingen 
of het toepassen van palliatieve sedatie vanwege onbehandelbare symptomen ten 
gevolge van een behandeling met opioïden in de stervensfase. Bij alle andere patiënten 
werd de uitkomst van behandeling als niet falen beschouwd. Omdat dit een exploratief 
(verkennend) onderzoek was, werden factoren met een p-waarde van < 0.10 in de 
univariate analyse, geïncludeerd in de multivariabele analyse en werden de data niet 
gecorrigeerd voor multiple testing (hoe meer factoren onderzocht worden, hoe groter 
de kans dat er verschillen gevonden worden). Met multivariabele analyse vonden we dat 
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lagere leeftijd, het gebruik van aanvullende pijnmedicijnen en de ernst van pijn in rust 
geassocieerd waren met het falen van behandelingen met fentanyl, morfine en oxycodon. 
Ook werd bij de single nucleotide polymorphisms (SNP’s; een variatie in het DNA van 
één enkele nucleotide lang) rs12948783 (RHBDF2) en alleen in het oxycodon cohort bij 
rs7016778 (OPRK1) een trend gezien in de richting van een negatief verband met falen op 
behandeling. De rol van deze twee genetische variaties moet verder worden onderzocht, 
temeer omdat de RHDBF2 SNP ontdekt is in een genoom brede associatie studie waarin 
patiënten met de bestudeerde variant minder goede pijnstilling hadden van opioïden 
terwijl in onze analyse het tegenovergestelde werd gevonden, namelijk een lagere kans 
op falen van behandeling bij dragers van deze genetische variant. De verbanden tussen de 
klinische factoren en het falen van behandeling waren niet onverwacht, hoewel de relatie 
tussen leeftijd en uitkomst van behandeling interessant is. Geen van de gevonden factoren, 
behalve misschien de OPRK1 SNP is specifiek voor een bepaald type opioïd, waardoor 
deze factoren de keuze voor een bepaalde behandeling niet kunnen sturen. Belangrijk 
is ook, dat geen van de SNP’s die gerelateerd zijn aan het metabolisme van specifieke 
opioïden (CYP3A4, CYP2D6, OCT1, UGT2B7 en ABCC3) een samenhang vertoonden met 
falen van behandeling in deze analyse, hetgeen de bevindingen die in hoofdstuk 5 werden 
beschreven ondersteunt. 
Algemene conclusies en aanbevelingen voor de 
toekomst
Ondanks alle hierboven beschreven inspanningen, zijn we nog ver weg van het echt 
individualiseren van behandeling met opioïden door gebruik te maken van prognostische 
en predictieve factoren. Dit lijkt tenminste deels een gevolg te zijn van ons onvolledige 
begrip van de werkingsmechanismen van opioïden en daarbij betrokken pathways 
(routes). Deze bevinden zich op het niveau van de receptoren, de cellen en in de 
modulerende systemen binnen het centraal zenuwstelsel. Hoewel er veel vooruitgang 
is geboekt in de afgelopen jaren, blijft het een uitdaging om de bevindingen vanuit de 
verschillende onderzoeksgebieden te integreren (10). Zodra we alle factoren kennen die 
de uitkomsten van behandeling kunnen beïnvloeden, kunnen we de effecten van variaties 
in deze factoren op de uitkomsten van behandeling meer gestructureerd onderzoeken. 
Hierbij kunnen we leren van de veelheid aan onderzoeken bij kanker, waarbij de biologie 
van kanker stap voor stap is ontrafeld waardoor gerichte behandelingen en combinaties 
van behandelingen konden worden ontwikkeld. 
Het gebrek aan goed opgezette studies met opioïden maakt het onmogelijk om harde 
conclusies te trekken over de rol van klinische factoren bij specifieke opioïden. Er is 
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behoefte aan door onderzoekers opgezette klinische studies van hoge kwaliteit. Om dit 
mogelijk te maken, moeten dergelijke studies gefinancierd worden door onafhankelijke 
partijen en moeten we de aanname dat onderzoek doen bij patiënten in de palliatieve fase 
onethisch of moeilijk uitvoerbaar is, loslaten. Het includeren van patiënten in palliatieve 
zorg studies kent geen unieke risicofactoren, hoewel er wel vaker een opeenstapeling is 
van factoren die de inclusie bemoeilijken. Voorbereiding hierop, bijvoorbeeld door middel 
van een speciaal voor dit doel gemaakt checklist, kan problemen voorkomen of tenminste 
verminderen (11). Verder moet internationaal consensus gezocht worden over het gebruik 
van gevalideerde beoordelingsschalen voor pijn en bijwerkingen specifiek voor palliatieve 
zorg, zoals ook gesuggereerd werd in een recent verschenen Cochrane review (12). 
Aangaande de farmacokinetiek studies is een van de moeilijkheden dat de opioïd 
receptoren zich voornamelijk in het centrale zenuwstelsel bevinden. Omdat de effecten 
van opioïden afhankelijk zijn van de concentratie van opioïden bij deze receptoren, zou 
wellicht eerst onderzocht moeten worden wat het verband is tussen de concentraties in 
plasma (bloed) en liquor (hersenvocht). Hoewel er beperkt onderzoek is gedaan op dit 
gebied (13-16), is onze kennis voor de verschillende opioïden momenteel niet toereikend. 
Om de belasting voor patiënten zo laag mogelijk te houden, zouden studies waarbij liquor 
en plasma worden onderzocht uitgevoerd kunnen worden bij gezonde vrijwilligers of 
zouden samples kunnen worden afgenomen bij patiënten die opioïden gebruiken en om 
een andere reden een ruggenprik moeten ondergaan. Verder zou bij het opzetten van PK 
studies de uitdaging moeten zijn de studie zo op te zetten dat het aantal samples zo beperkt 
mogelijk gehouden kan worden, door goede timing en door het beperken van verstorende 
factoren (zoals aanpassingen in de dosering of extra doses). De uitdaging zal zijn om de 
klinische praktijk zo min mogelijk te verstoren en zo de belasting van studiedeelname 
voor patiënten zo laag mogelijk te houden, terwijl tegelijkertijd de omstandigheden voor 
uitvoering van de studie zo optimaal mogelijk zijn. Toekomstige studies kunnen zich 
bijvoorbeeld richten op het onderzoeken van het verband tussen spiegels van opioïden 
in bloed en liquor, op het vinden van methoden om een meer stabiele bloedspiegel van 
fentanyl te krijgen bij toediening door middel van pleisters en op het optimaliseren van 
rotatie schema’s voor zowel veranderingen in toedieningsroute als in type middel. Om de 
effecten van genetische variaties beter te kunnen onderzoeken, zouden we idealiter eerst 
meer kennis moeten hebben van factoren in verschillende pathways die van invloed zijn 
op de uitkomsten van behandeling, zodat we gericht het effect van (farmaco-) genetische 
variaties in deze factoren kunnen onderzoeken. Doordat de uitkomsten van behandeling 
het gevolg lijken te zijn van een ingewikkeld samenspel tussen klinische, genetische en 
farmacokinetische factoren, lijkt het echter onwaarschijnlijk dat één SNP een significant 
effect zal hebben. Daarom moeten we ons misschien richten op het vinden van groepen 
van genen door combinaties van SNP’s te maken die betrokken zijn bij de verschillende 
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pathways. Zolang we deze pathways echter onvoldoende kennen en begrijpen, kunnen 
genoom brede associatie studies (studies waarbij alle bekende genen onderzocht worden 
en waarbij naar verschillen tussen bepaalde groepen kan worden gezocht) helpen bij het 
vinden van relevante SNP’s. Zulke studies moeten echter uitgevoerd worden in grote, 
homogene groepen van patiënten en vereisen objectieve criteria voor het vaststellen van 
falen op een behandeling. Dat maakt zulke studies moeilijk uitvoerbaar. 
Tot slot hebben wij, doordat weinig onderzoek wordt gedaan naar opioïden en dit als te 
specifiek wordt gezien voor medische tijdschriften gericht op kanker, soms moeite gehad 
met het vinden van een geschikt tijdschrift om onze bevindingen in te publiceren. Wij zijn 
van mening dat dit deels het gevolg is van het feit dat niemand zich ‘eigenaar’ voelt van 
palliatieve zorg terwijl het juist voor vrijwel iedere behandelaar belangrijk is. Omdat pijn 
veel voorkomt bij patiënten met kanker, zouden alle behandelaars die betrokken zijn bij 
de behandeling van patiënten met kanker ook kennis moeten hebben over de behandeling 
van kanker gerelateerde pijn. Hopelijk leidt de huidige aandacht voor palliatieve zorg 
op het politieke, maar ook het publieke vlak, tot meer aandacht voor wetenschappelijk 
onderzoek op dit gebied en leidt dat weer tot betere publicatie mogelijkheden waarmee 
een breed medisch publiek kan worden bereikt. 
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Dankwoord
In de afgelopen jaren is mij (heel erg) vaak gevraagd of er nog een 3e kind zou komen. En 
net zo vaak heb ik geantwoord dat dit boekje mijn 3e ‘kind’ zou worden. Dat leverde soms 
vragende of zelfs bezorgde blikken op. De analogie tussen het krijgen van een kind en het 
schrijven van een proefschrift is echter vaker getrokken, en terecht. Vreemd? Zeker niet, 
ik zal u uitleggen waarom aan de hand van eigen ervaringen tijdens mijn promotietraject. 
Ten eerste: hoewel ik weldegelijk bij de totstandkoming van dit promotietraject betrokken 
was, is het me toch een beetje overkomen en was het aanvankelijk ook niet erg gewenst. 
(Om verwarring te voorkomen: mijn zwangerschappen waren zeer gewenst.) Maar toen ik 
eenmaal aan het onderzoek begonnen was kon en wilde ik niet meer terug. Ik raakte aan het 
idee gewend en begon steeds meer uit te kijken naar de resultaten. Het eindresultaat begon 
steeds meer vorm te krijgen: waar ik in het begin geen idee had waar al mijn inspanningen toe 
zouden leiden, kwam uiteindelijk dit tot in detail uitgewerkte boekje tot stand. 
Ten tweede: hoewel het schrijven van dit proefschrift ietsje langer duurde dan 9 maanden, 
had ook het beloop overeenkomsten met een zwangerschap. De kern is eigenlijk dat het 
beloop nogal wisselt terwijl je daar niet of nauwelijks invloed op hebt. Het gaat zoals het 
gaat en het komt zoals het komt, je kunt je er maar het beste aan overgeven. 
Ten derde: hoewel het heel verstandig is om voor je 40e, en bij voorkeur nog veel eerder 
kinderen te krijgen/ een proefschrift te schrijven, maken de omstandigheden soms dat de 
dingen anders lopen. En zo kan het zijn dat je toch na je 40e nog een kind krijgt of in mijn 
geval (net….) na je 40e promoveert.  
Waar de vergelijking mank gaat is dat voor het ‘maken’ van een kind meestal slechts 2 
mensen nodig zijn. Voor de totstandkoming van dit proefschrift waren dat er vele meer. 
Een aantal mensen wil ik in het bijzonder bedanken voor hun bijdrage in wetenschappelijke 
en/of persoonlijke sfeer. 
Ten eerste mijn promotor Prof. Dr. C.C.D. van der Rijt. Beste Karin, veel dank voor je 
begeleiding en kritische meedenken. Onze karakters zijn op veel punten tegenovergesteld 
en het heeft even geduurd voordat we een modus vonden om tot goede samenwerking 
te komen. Maar dat is gelukt, en hoe. Jouw drang om alles te willen begrijpen en jouw 
kritische blik hebben mijn werk verbeterd. Je hebt mij altijd begrepen en gerespecteerd 
en hebt me alle ruimte gelaten om de dingen op mijn manier te doen, en daar heb ik veel 
bewondering voor. Laten we samen verder bouwen binnen onze afdeling.
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Mijn tweede promotor, Prof. Dr. A.H.J. Mathijssen. Beste Ron, van opleidingsmaatje ben 
je nu mijn promotor geworden. Jouw enthousiasme werkt aanstekelijk en motiverend. 
Je snelle commentaar op alles dat ik je stuurde maakte dat de vaart erin bleef, behalve 
als je mailbox weer eens vol bleek te zijn. Wanneer je met het al het fraaie onderzoek dat 
je doet zoveel lof oogst als jij, is het niet gemakkelijk om te ervaren dat er voor het type 
onderzoek dat wij samen uitgevoerd hebben minder animo is. Daar moeten we wat aan 
doen! 
De leden van de leescommissie, Prof. Dr. R.H.N. van Schaik, Prof. Dr. M. J. van den Bent 
en Prof. dr. P.C. Huijgens: veel dank voor jullie kritische lezen en positieve beoordeling van 
dit proefschrift.
De overige leden van de promotiecommissie: Patricia van den Bemt, An Reijners, Siv 
Jönsson, Robert-Jan Stolker en Stefan Sleijfer; veel dank voor jullie bereidheid om met mij 
van gedachten te wisselen op 9 december.
En dan: iedereen die heeft geholpen bij de uitvoering van de studies. Zeer veel dank ben ik 
verschuldigd aan alle patiënten die hun medewerking hebben verleend aan de onderzoeken 
die in dit boekje staan beschreven. Wanneer je pijn hebt is het niet gemakkelijk om een 
stap extra te zetten en je over te geven aan extra vragen en/of extra bloedafnames. Wat 
geweldig dat jullie een bijdrage hebben geleverd aan een betere behandeling van pijn. 
Velen van u waren steeds opnieuw geïnteresseerd in de onderzoeken waaraan u al dan 
niet deel hebt genomen en ik werd steeds opnieuw geraakt door uw persoonlijke interesse 
voor mij, als mens, werkende aan deze onderzoeken. 
De verpleegkundigen op de afdelingen B1, B0, B0Zuid en voormalig A0: ook jullie 
hebben we extra inspanningen gevraagd. Veel dank voor ieders inzet rondom alle extra 
bloedafnames, het verzamelen van urine en de benodigde registraties. We verkeren in 
de unieke omstandigheid om dit soort onderzoek te kunnen doen en ik hoop dat jullie 
gemotiveerd zullen blijven om daar een bijdrage aan te leveren.
De dames van de VCPT, in het bijzonder Tilly Baan. Tilly, wat heb je hard aan de ‘opioïdstudie’ 
getrokken. Dankzij jou bleef de inclusie op gang, werd er beter geregistreerd en was er 
nog enige orde in de bloedafnames. Heel veel dank voor je enorme inzet.
Iedereen betrokken bij de PK studies. Walter Loos: dank voor het opzetten van de essays 
en de logistiek daaromheen. Peter: jij hield het overzicht in fraaie Excel sheets en hebt alle 
samples doorgemeten. Zonder jou hadden we deze studies nooit kunnen doen. 
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Siv Jönsson and João Abrantes. I don’t know where to begin… When we started to work on 
the PK studies, I had never heard of NONMEM and had no experience with PK studies at 
all. Nonetheless, you have had the patience to teach me how to build a NONMEM dataset, 
correct endless mistakes in it and explain all steps in the analyses. You always remained 
calm and friendly, even when I was pressuring you because of time issues. It was a pleasure 
to work with you and I am very happy to finally meet you in person on the 9th of December.
Iedereen betrokken bij de PG analyses. Anne-Joy: jij beheerde de samples en wist ze op 
de juiste momenten ook weer snel te vinden, waarvoor dank! Maja, jij hebt me wegwijs 
gemaakt in de wereld van de SNP’s en hebt alle genotyperingen uitgevoerd. Veel succes 
met de afronding van jouw promotietraject en wat daarna komt. Ron, dank voor het 
mogelijk maken van alle genotyperingen in jouw laboratorium.
Dan de statistici. Paul, Wendim en Maxime: gelukkig zijn jullie ook van de geduldige soort. 
Maxime, we hebben heel wat woensdagochtenden met elkaar doorgebracht, waarin 
we eindeloos hebben geworsteld met data en vooral met de dataset. Je hebt je in ons 
project vastgebeten en er ook nog eens eindeloos veel thuis uren ingestoken. Daarvoor 
kan ik je niet genoeg bedanken. Daarnaast heb ik heb veel van je geleerd op werk- maar 
ook op persoonlijk vlak. Het was fijn om je beter te leren kennen, ik zou het heel leuk 
vinden om contact met je te houden na je naderende pensionering. Veel succes met jullie 
woonproject, ik ben heel benieuwd hoe dat uitpakt.
Iedereen die betrokken is geweest bij het (opnieuw) bouwen en vullen van de database: 
Kirsten, Rene, Nelly, Jessica, Regine, Caroline, Petra, Ellen, Tarik, Armina en Zubeyde. Het 
was een hele tour om een goede dataset te bouwen, te verhuizen, te corrigeren en te 
vullen. Maar het is gelukt! Veel dank voor alle uren die jullie daarin gestopt hebben. 
Alle collega’s die me de ruimte hebben gegeven om dit onderzoek te doen en jarenlang 
– of jullie dat nu wilden of niet – deelgenoot werden gemaakt van alle ups en downs. 
Ik kon altijd bij jullie terecht en velen van jullie hebben op enige wijze bijgedragen aan 
dit proefschrift. Ronald, Marijke, Agnes, Esther, Wim, Caroline, Stefan, Maja, Martijn, 
Marjolein, Stefan, Ate, Ferry, Lia en Ingrid: veel dank!
Alle dames van het secretariaat interne oncologie, in het bijzonder Gerdien. Hoewel ik 
altijd denk het allemaal zelf te kunnen,  is het jullie toch gelukt om mij op vele manieren te 
ondersteunen in dit traject. Veel dank daarvoor en blijf vooral proberen!
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Wendy, jij bent me op vele manieren tot steun geweest tijdens dit traject. Ten eerste heb 
je het kunnen opbrengen om meer dan 5000 titels te screenen voor ons systematische 
review waarna je de overgebleven papers tot in detail hebt uitgeplozen. Ook jouw bijdrage 
aan de beroemde stippenfiguur is onmisbaar geweest. Maar naast jouw bijdrage aan het 
review heb ik ook veel gehad aan jouw ervaring met onderzoek doen binnen de palliatieve 
zorg, en met promoveren. Fijn dat ik altijd bij je terecht kan om even te spuien. 
Dan, alle promovendi die in de afgelopen jaren voorbij zijn gekomen. Als promoverend 
staflid was ik een vreemde eend in de bijt, toch was ik bij jullie altijd welkom. Jacqueline, 
veel dank voor je hulp bij het maken van en vervoeren van mijn poster en voor de vele 
gezellige momenten zowel in Rotterdam als Chicago. Je keuze voor de reumatologie blijft 
moeilijk te begrijpen, maar je hebt het in je om een goede reumatoloog te worden. Sander, 
jouw droge humor kwam vaak op het juiste moment. Ik zal voortaan voorzichtiger zijn bij 
het vullen van waterballonnen in jouw aanwezigheid. Roelof, jij ging mij eerder dit jaar 
voor, dank voor je praktische adviezen en de gezelligheid bij verschillende gelegenheden. 
Jildou, Maureen en Laila en natuurlijk de mannen, Gerben, Roy en Eduard. Onze 
vriendschappen begonnen meer dan 20 jaar geleden (….) en hebben de tijd en de afstand 
overleefd. Hoewel we elkaar weinig zien, is het wanneer we elkaar zien altijd gelijk goed. 
Ik heb erg genoten van onze culinaire trips in de afgelopen jaren, laten we dat vooral 
blijven doen! 
Evelien, geweldig dat je naast me staat op deze dag! Onze tijd samen in het Erasmus 
MC was kort maar krachtig. Het was heel fijn om met jou in hetzelfde schuitje te zitten, 
maar erg jammer dat onze duo-promotie niet is gelukt. Veel dank voor je gezelligheid, 
steun, opbeurende woorden en al het werk dat je gedaan hebt om mij tijd te geven voor 
onderzoek. Succes met het afronden van jouw promotietraject en met het opbouwen van 
mooie dingen in en rond Nijmegen.
Maike, wie anders dan jij moet er naast me staan op deze dag. Sinds dat 1e sigaretje en die 
oranje tuinbroek is er heel veel veranderd en toch ook weer niet. Onze vriendschap staat 
als een huis, ondanks het feit dat we elkaar maar weinig kunnen zien. Ik ben heel blij te 
weten dat je er altijd voor me bent. Door dik en dun. 
Papa en mama, wat ben ik jullie veel dank verschuldigd. Jullie hebben mij altijd op alle 
mogelijke manieren ondersteund en mij mijn eigen keuzes laten maken. Dankzij jullie heb 
ik een onbezorgde jeugd en studententijd gehad. Ik, maar ook Bas en de kinderen, kunnen 
altijd op jullie rekenen. Dankzij jullie stabiele basis heb ik mezelf kunnen ontplooien en 
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daarvoor ben ik jullie zeer dankbaar. 
Elsa en Olaf, hoewel ik dit boekje gekscherend mijn 3e kind heb genoemd, zijn jullie me 
heel veel dierbaarder. Jullie geven kleur aan mijn leven. Mama’s boekje is eindelijk af, het 
is tijd voor feest!
Lieve Bas, zonder jou had ik dit echt niet kunnen doen. Ik ben je ontzettend dankbaar voor 
je onvoorwaardelijke steun,  voor alle uren die je alleen met de kinderen doorbracht terwijl 
ik op zolder zat en voor het accepteren van onze beperkte actieradius in de weekeinden. 
Dit jaar is nogal tumultueus verlopen, gelukkig hebben we dat samen kunnen doorstaan. 
Ik wil niets liever dan samen met jou aan een volgend hoofdstuk beginnen.
En nu: tijd voor een drankje en een dansje!
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Curriculum Vitae
Astrid Oosten werd op 25 september 1976 geboren te Amsterdam. In 1994 behaalde zij haar 
VWO-atheneum diploma aan het Christelijk College Nassau Veluwe te Harderwijk. Daarna 
volgde een studie geneeskunde aan de Rijks Universiteit Groningen. In 2001 behaalde 
zij daar cum laude haar artsexamen. Van januari 2001 tot november 2002 werkte zij als 
AGNIO interne geneeskunde in de Isala Klinieken te Zwolle. In november 2002 startte de 
opleiding tot internist in het Martini Ziekenhuis in Groningen (opleider Dr. R.S. de Jong). 
Van juni 2006 tot februari 2007 werd de opleiding vervolgd in het Universitair Medisch 
Centrum Groningen (opleider Prof. Dr. R.O.B Gans). In februari 2007 startte zij met de 
opleiding binnen het aandachtsgebied interne oncologie (opleider Prof. Dr. J. Verweij) in 
het Erasmus MC te Rotterdam. Vanaf juni 2009 werkt zij als staflid binnen de afdeling 
interne oncologie van het Erasmus MC Kanker Instituut. In 2010 werd, onder begeleiding 
van Prof. Dr. C.C.D. van der Rijt en Prof. Dr. A.H.J. Mathijssen, een begin gemaakt met de 
onderzoeken die beschreven staan in dit proefschrift.
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PhD Portfolio
Summary of PhD training and teaching activities
Name PhD student: A.W. Oosten
Erasmus MC Department: Medical oncology
PhD period: January 2010 – July 2016
Promotor(s): Prof dr. CCD van der Rijt and 
Prof. dr. A.H.J. Mathijssen
1. PhD training
Year Workload
 ECTS
General academic skills 
Research Integrity
Good clinical practice 
BROK (‘Basiscursus Regelgeving Klinisch Onderzoek’)
BROK recertification
2010
2011
2015
0.4
1 
0.5
In-depth courses (e.g. Research school, Medical Training)
6-day Course Palliative care for medical specialists 2011 2
Presentations
Oral presentation for Oncology TV
Oral presentation Research meeting Expertise center for palliative care 
Oral presentation ZonMW meeting for researchers in palliative care 
Oral presentations Scientific Meeting dept. of Oncology
ASCO poster presentation (abstract number 9540)
Interview oncology TV ‘pharmacokinetics of fentanyl’
Amsterdam symposium on palliative care 
Medical Oncology Research Meeting 
2011
2011
2012
2011 & 2014
2014
2014
2015
2016
0.5
0.5
1
1
1
0.5
0.5
1
(Inter) National conferences
Year symposium ‘continuum oncology’ 
Research meetings Erasmus MC Medical Oncology
ECCO/ESMO conference (2010, Berlin, Germany)
ESMO conference (2012, Vienna, Austria)
‘Internistendagen’ 
Post-ASCO 
ESMO conference (2013, Amsterdam)
National conference ‘cancer in the elderly’ 
ASCO Annual meeting (2014, Chicago)
‘De dokter en de dood’
Amsterdam symposium on palliative care 2015
ASCO Annual meeting (2016, Chicago) 
2010-2016
2010-2016
2010
2012
2013
2013/2015
2013
2013
2014 
2015
2015
2016
2
1.5
1.2
1.2
0.6
0.8
1.2
1
1.2
1
1
1.2
Seminars and workshops
Regional meeting Pain IKNL 
Workshop communicating with cancer patients 
OMBO courses dept. of medical oncology
Research meetings Expertise Center for palliative care
Seminar: ‘U vraagt wij draaien’
Workshop Stichting STEM
2011
2011
2010-2016
2010-2015
2011
2012
0.3
0.3
1.5
1
0.2
0.2
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1. PhD training
Didactic skills
Teach the teacher training 
Member Education Committee dept of Medical Oncology 
Education ANIOS/AIOS Medical Oncology Erasmus MC
Trainer General Practitioners palliative care internship
2010
2010 - 2015
2009 - 2016
2012 - 2016
1
2
4
2
2. Teaching activities
Lecturing
Oncology nurses teaching days, several lectures 
OIO meetings ‘pharmacokinetics of fentanyl and morphine’ 
Monodisciplinary teaching sessions medical oncology
Case meetings Tumour working group pain 
Nursing theme afternoon: Palliative care 
Zorgacademie Erasmus MC: Pain and pain control in palliative care
GIST patient support group contact day: Workshop palliative care 
2010 -2013 
2012 and 2014
2011 - 2016
2012 - 2016
2012
2013-2016
2014
3
2
2
1
1
4
1
Supervising practicals and excursions
2nd year students elective course visit to palliative care unit
VSO skills in communicating bad news 
2010-2015
2015
0.4
0.4
Other
Supervising nurse practitioner palliative care in training 
Medical coordinator and supervisor clinical unit for palliative care and 
symptom control 
Coordinator of team ‘Nursing Specialists in Palliative care and Home 
Technologies’
2013-2014
2010-2016
2010-2016
4
10
6
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